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Pregnane X receptor (PXR, NR1I2) is a ligand-activated nuclear receptor (NR) 
superfamily member expressed at high levels in the liver and intestine of mammals.  PXR 
can be activated by a broad range of structurally diverse xenobiotics and endobiotics.  As a 
key regulator of xenobiotic metabolism and clearance, activated PXR up-regulates the 
expression of genes encoding phase I (oxidation) and phase II (conjugation) metabolizing 
enzymes and phase III transporters to increase the metabolism and clearance of drugs and 
xenobiotics from the body, thus protecting the body from potential toxic insults.  Besides 
xenobiotic metabolism and clearance, activation of PXR also involves in the regulation of 
many other important biochemical pathways, like inflammation and bile acid homeostasis.  
While ligand-binding is the primary mechanism for NRs activation, recent research indicates 
that post-translational modifications of NRs also help to determine their activities under 
different physiological conditions and represent new modes of regulation for NRs.   
Studies on post-translational modifications of PXR have just begun to emerge, how 
post-translational modifications regulate PXR activity is not well-understood.  This 
dissertation focuses on ubiquitination and SUMOylation of PXR.  These post-translational 
modifications of PXR were characterized and their effects on PXR activities were studied in 
both primary cultures of hepatocytes and immortalized cell lines.  Data presented here 
indicate that PXR is a target of the ubiquitin proteasome system, and inhibition of proteasome 
activity decreases the transactivation of PXR.  The E3s and SENPs (Sentrin-specific 
Protease) that regulate PXR SUMOylation and de-SUMOylation are identified.  Utilizing 
the newly identified SENPs, SUMOylation is further confirmed to be indispensable for PXR 
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to repress inflammatory response.  Furthermore, the crosstalk between ubiquitination and 
SUMOylation at the level of PXR is explored.  Our data indicate that SUMOylation 
increases the presence of ubiquitinated PXR, and many other substrates of ubiquitin.  Taken 
together, this dissertation contributes to the understanding of post-translational modifications 
of PXR and their regulatory effects on drug metabolism and inflammation, which is expected 
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1. 1 Nuclear Receptors 
Nuclear receptors (NRs) are a family of ligand-activated transcription factors.  They 
can sense the presence of their ligands, like steroids, retinoids, and hormones, to regulate the 
expression of their target genes.  Through this mechanism, NRs participate in development, 
metabolism, and homeostasis among other processes, and their activities are closely 
associated with diseases related to these processes (1).  Moreover, since most ligands that 
bind to NRs are small lipophilic molecules that can be easily synthesized and modified, NRs 
have gained great attention as therapeutic targets.  Currently, molecules that target NRs 
make up approximately 13% of U.S. Food and Drug Administration (FDA) approved drugs 
(2).  Some examples of NRs as therapeutic targets include androgen receptor (AR, NR3C4) 
antagonists in the treatment of prostate cancer, estrogen receptor α (ERα, NR3A1) antagonists 
in the treatment of breast cancer, and peroxisome proliferator-activated receptor γ (PPARγ, 
NR1C3) agonists in the treatment of type II diabetes.  Their fundamental roles and their 
potential as therapeutic targets make studies of NRs of great importance. 
1.1.1 The Structure of Nuclear Receptors  
A characteristic multi-domain structure is shared by most NRs.  From N-terminus to 
C-terminus, there is N-terminal modulatory domain (A/B region), DNA binding domain 
(DBD, C region), hinge region (D region), ligand binding domain (LBD, E region), and 





Figure 1-1. Structure of Nuclear Receptors.  A characteristic multi-domain structure 
is shared by most NRs.  From N-terminus to C-terminus, there is N-terminal modulatory 
domain (A/B region), DNA binding domain (DBD, C region), hinge region (D region), ligand 








region among different domains within the NR family.  AF-1 (Activation Functions 1) 
sequence resides in this domain.  AF-1 functions as a ligand-independent transactivation 
domain.  The activation capacity of AF-1 varies considerably between different NRs.  The 
DBD binds to DNA, as indicated by its name.  The structure of DBD is highly conserved 
within the NR family.  There are two zinc fingers in DBD that can bind to specific DNA 
sequences and position NRs to their binding sites.  The zinc finger binding sequences are 
disparate among different NRs and these diverse sequences are known as hormone response 
elements (HREs).  HREs locate not only in the vicinity of target gene promoters, but also in 
intronic and enhancer regions.  The DBD is connected with the LBD by the hinge region, 
which contains a nuclear localization signal.  For most NRs, the LBD is structured as a 
three-layered antiparallel α-helical sandwich by eleven or twelve α-helices and two to four 
β-strands.  Three parallel α-helices together with β-strands are flanked by two layers of 
α-helices on both sides, forming the sandwich structure.  The ligand binding pocket of LBD 
is located below the three parallel α-helices (3).  The shape of the ligand binding pocket, 
hydrophobic interactions, hydrogen-bonding, and the steric size together with other factors 
determine the binding between ligands and LBDs (4).  Compared to DBD, the structure of 
LBD is less conserved within the family.  The ligand-dependent transcription activator, 
AF-2, is located within the LBD.  In most cases, activation of AF-2 is much stronger than 
AF-1.  AF-1 synergizes with AF-2 to achieve full transcriptional activity (5).  However, 
there are exceptions.  For instance, AF-1 is responsible for the majority of AR activity (6).  
The C-terminal domain is highly variable in sequence between different NRs and the structure 
and function of this domain are not well-known yet.  Recent studies indicate that the 
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C-terminal domains are also closely related to NR activities.  Deletion of the C-terminal 
domain of ERα eliminates the transactivation of ERα to certain agonists.  The C-terminal 
domain of hepatocyte nuclear factor 4 alpha (HNF4α, NR2A1) interacts with the silencing 
mediator for retinoid or thyroid-hormone receptors (SMRT), and contributes to the regulation 
of HNF4α activities (7, 8).  
It is generally believed that NRs are specific to metazoans (9).  Based on structural 
similarity mentioned above, 48 NRs are identified in the human genome.  The numbers of 
NRs in mice and rats are similar to human, with 49 NRs in mice and 47 in rats.  In 
Drosophila, there are 21 receptors.  However, there are up to 284 receptors in C. elegans (10, 
11).  Exceptions in NR structure do exist.  Dax1 (dosage-sensitive sex reversal, adrenal 
hypoplasia critical region, on chromosome X, gene 1, NR0B1) and SHP (small heterodimer 
partner, NR0B2), two atypical orphan members of the NR subfamily, lack DBDs (12, 13).  
Nurr1 (Nuclear receptor related 1 protein, NR4A2) and the drosophila NR DHR38 lack 
detectable ligand binding pockets within their LBDs (14, 15).  Many NRs are identified by 
sequence similarity to known receptors.  At the time of their identification, cognate ligands 
to some newly identified NRs remain unknown, and these NRs are referred as “orphans”.   
When ligands for orphan NRs are identified, the “orphans” will be adopted.  Pregnane X 
receptor (PXR, NR1I2), the focus of this dissertation, is one well-known adopted orphan NR. 
NRs can bind to HREs as monomers or as either homodimer or heterodimer with 
retinoid X receptor (RXR, NR2B).  Based on their dimerization pattern and DNA binding 
properties, NRs can be divided into four different types.  Type I NRs function as 
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homodimers and bind to DNA half-sites organized as inverted repeats.  Within this group are 
steroid receptors, including estrogen receptor α/β (ERα/β, NR3A1/2), glucocorticoid receptor 
(GR, NR3C1), mineralocorticoid receptor (MR, NR3C2), progesterone receptor (PR, NR3C3), 
and androgen receptor (AR, NR3C4).  In the absence of ligands, type I NRs are sequestered 
in cytosol by chaperone proteins like heat shock proteins (HSPs).  Ligand binding can lead 
to a conformation change of NRs and dissociate chaperone proteins.  After the dissociation, 
liganded NRs translocate to the nucleus and bind to DNA to regulate the expression of their 
target genes.  Type II NRs form heterodimers with RXR and bind to direct repeats.  
Examples from this family include thyroid receptor α/β (TRα/β, NR1A1/2), vitamin D 
receptor (VDR, NR1I1), retinoic acid receptor α/β/γ (RARα/β/γ, NR1B1/2/3), and 
peroxisome proliferator-activated receptor α/β/γ (PPARα/β/γ, NR1C1/2/3).  Unlike type I 
NRs, type II NRs are constitutively in the nucleus.  Without ligands, the NR heterodimers 
bind to DNA with corepressor complexes and actively repress the expression of target genes.  
When ligands are present, the binding of ligands changes the conformation of NR 
heterodimers and leads to the expression of target genes.  Some NRs like RAR-related 
orphan receptor α/β/γ (RORα/β/γ, NR1F1/2/3) and steroidogenic factor 1 (SF-1, NR5A1) can 
bind DNA as monomers.  NRs that act as monomers and NRs that bind to direct repeats as 
homodimers are classified as the other two classes (1).  
1.1.2 Nuclear Receptors and Co-regulatory Proteins 
NR-mediated gene expression is a dynamic process, which is rigorously controlled by a 
series of exchanges between NRs and co-regulatory proteins.  Both activation and repression 
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of NRs require the cooperation of co-regulatory proteins.  In general, without ligands, NRs 
are associated with corepressor complexes, which actively repress the expression of target 
genes.  The most well-studied corepressor proteins are nuclear co-repressor (NCoR) and 
SMRT.  Neither NCoR nor SMRT has intrinsic enzymatic activity, but they function as 
platform proteins to recruit complexes that contain chromatin-modifying enzymes like histone 
deacetylases (HDACs) and many other enzymes (16-19).   By deacetylating histones, 
HDACs generate a condensed chromatin structure to repress transcription.  When ligands are 
present, the binding of ligands leads to a conformational change of the LBD.  The 
corepressor complexes then dissociate from NRs.  After the corepressor complexes are 
cleared from the promoter, coactivators together with the basal transcriptional machinery can 
be recruited to NRs to initiate the transcription of target genes (20).  Steroid receptor 
coactivators (SRCs) are among the best characterized coactivators.  They act as bridging 
factors between NRs and other co-regulators like histone acetyltransferases (HATs) through 
protein-protein interactions.  Corepressor complexes and coactivators are large multiprotein 
complexes.  Components in these complexes may have different enzymatic capabilities 
including acetyltransferase, methyltransferase, phosphokinase and ATPase activities.  Both 
corepressor complexes and coactivators bind to the hydrophobic groove formed by α-helices 
on the surface of LBD.  Because of the overlapping of binding sites, binding of corepressor 
complexes and coactivators are mutually exclusive.  
To date, hundreds of co-regulatory proteins have been identified.  As essential 
components of NR signaling, co-regulatory proteins regulate chromatin modifications, 
mediate crosstalk between different NRs, and contribute to cell-specific transcriptional 
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responses to a given receptor (21).  Co-regulatory proteins are under the regulation of 
signaling pathways, and their activities are directly influenced by their post-translational 
modification (PTMs) status.  For example, phosphorylation of SRC-3 on different residues 
can lead to selective activation of certain NRs and non-NR transcription factors (22).  
Phosphorylation of NCoR and SMRT can regulate their intracellular localization (23).  The 
transcriptional activities and transcription factor preferences of co-regulatory proteins can be 
different in disparate cell types and signaling contexts.  Sometimes the distinction between 
coactivators and corepressors can be blurred.  They can even switch roles under certain 
conditions (24, 25).  Misexpression and malfunction of co-regulatory proteins have been 
shown to be associated with numerous physiological abnormalities and diseases, including 
type II diabetes, cancer and some inherited genetic syndromes (26).  With the increasing 
understanding of co-regulatory proteins, they have begun to gain attention as potential 
therapeutic targets. 
1.1.3 Post-Translational Modifications of Nuclear Receptors 
Activities of NRs are mainly regulated by their ligands and co-regulatory proteins, but 
their functions can also be influenced by PTMs.  PTM is a process in which amino acid 
residues in a protein are covalently modified by other molecules or proteins.  PTMs, like 
phosphorylation, SUMOylation, and acetylation, fine-tune the activities of NRs through the 
regulation of NR subcellular localization, dimerization, DNA binding, and co-regulator 
interactions.  Potentially, every NR can be regulated by PTMs.  Recently, PTMs of NRs 
have drawn much attention and interesting research has emerged. 
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1.1.3.1 Phosphorylation of NRs 
The most extensively studied PTM of NRs is phosphorylation.  Most NRs are 
phosphorylated at multiple sites in both ligand-dependent and –independent manners.  
Phosphorylation regulates transcriptional activities of NRs and provides a way to integrate the 
physiological context of cells and activities of NRs.  In general, phosphorylation is a positive 
regulator for NR activities, though in some cases, it can also lead to transcriptional repression.  
For instance, cyclin-dependent kinase 9 (CDK9) together with other CDKs can 
phosphorylate AR on S81.  Treatment of CDK9 inhibitors decreases S81 phosphorylation 
and also AR-mediated transcription (27).  Growth factors can activate ERα in a 
ligand-independent manner through the phosphorylation of ERα (28).  For GRα 
phosphorylation, both the pattern and extent are influenced by different glucocorticoids 
presented (29).  Different phosphorylation patterns can lead to different effects on GRα 
transcriptional activity.  Phosphorylation at S211 leads to increased transcriptional activity, 
whereas phosphorylation at S226 leads to decreased transcriptional activity (30, 31).  
Moreover, stress-activating stimuli can phosphorylate GRα in a ligand-independent manner at 
S134 and lead to a blunted transcriptional response of select genes (32).  Phosphorylation of 
PRs by MAPKs (mitogen-activated protein kinases) leads to ultra-sensitivity of PRs to one of 
its ligands, progestins (33). 
Since phosphorylation can regulate the activities of NRs and lead to different 
transcriptional outcomes, phosphorylation of NRs has emerged as a potential therapeutic 
target.  For example, phosphorylation of GR by p38 MAPK can lead to reduced 
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responsiveness to glucocorticoid treatment in patients with asthma.  p38 MAPK inhibitors 
have been shown to increase the anti-inflammatory effects of glucocorticoids and re-establish 
the beneficial effects of glucocorticoids in glucocorticoid-resistant asthma (34).  CDK5 
phosphorylates PPARγ at S273 and decreases PPARγ transcriptional activity.  Blocking 
CDK5-mediated PPARγ phosphorylation by non-agonistic binding has been demonstrated to 
produce anti-diabetic effects without some side effects of thiazolidinediones, suggesting that 
targeting the CDK5 phosphorylation event, instead of direct PPARγ agonism, may be a better 
way to treat insulin resistance and avoid side effects (35). 
1.1.3.2 Acetylation of NRs 
Protein acetylation is closely related to transcription.  Histone acetyltransferases (HATs) 
and histone deacetylases (HDACs) modify histones by adding or removing acetyl groups, 
generating either loosened or condensed chromatin structure to facilitate or repress 
transcription.  Besides its role in regulating chromatin structure, acetylation also directly 
modifies NRs and regulates their activities.   
Depending on target NRs, acetylation can either enhance or inhibit their transcriptional 
activities.  For instance, mutation of acetylation sites of AR leads to increased cytoplasmic 
localization and decreased transcriptional activity of AR in PC3 cells.  Inhibition of 
deacetylase activities increases acetylation level of AR and also its transcriptional activities 
(36, 37).  PR can be acetylated at K183 by p300 and p300-mediated acetylation leads to 
increased PR activity (38).  GR becomes acetylated in response to glucocorticoid binding.  
Unlike the NRs discussed above, acetylation of GR by the circadian rhythm-related 
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transcription factor “clock” represses GR activities (39).  Deacetylation of GR by HDAC2 is 
reported to be essential for the receptor to efficiently repress NF-κB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) activity, suggesting that acetylation of GR 
limits the inhibitory actions of glucocorticoids on NF-κB signaling (40).   
1.1.3.3 Ubiquitination of NRs 
Ubiquitination is a small covalent modification that has been identified on many NRs.  
Ubiquitination can lead to proteasome degradation of NRs.  However, the regulatory effect 
of ubiquitination on activities of NRs is achieved through both degradation-dependent and 
-independent manners. 
Polyubiquitination of AR can be catalyzed by ubiquitin E3 ligases MDM2 (Mouse 
double minute 2 homolog) and CHIP (C-terminus of Hsc70 interacting protein).  MDM2 and 
CHIP-mediated polyubiquitination of AR promotes its degradation and decreases AR 
transactivation (41, 42).  Ubiquitination of AR can be mediated by the ubiquitin E3 ligase 
RNF6 (RING finger protein 6) as well.  It has been shown that ubiquitination of AR is 
increased after ligand treatment, while knockdown of RNF6 significantly diminishes both 
basal and ligand-induced ubiquitination of AR.  Unlike MDM2 and CHIP, RNF6-promoted 
AR ubiquitination does not lead to its degradation, but enhances the transcriptional activity of 
AR (43).  Ubiquitination of GR has been shown to target the receptor for proteasome 
degradation and decrease GR transactivation (44).  Mutation of the GR ubiquitination site 
leads to resistance to ligand-dependent down regulation and potentiates transcriptional 
activities on glucocorticoid-responsive reporter genes (45).  All forms of PPARs have been 
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shown to be ubiquitinated.  Polyubiquitination of PPARβ and PPARγ inhibits their activities 
by promoting their degradation.  However, the scenario is much more complicated for 
PPARα.  The ubiquitination of PPARα is promoted by the E3 ligase, MDM2.  In transient 
transfection assays, when the MDM2-to-PPARα ratio is less than 0.5, ubiquitination leads to 
increased activity of PPARα.  However, when the MDM2-to-PPARα ratio is greater than 1.0, 
ubiquitination inhibits transactivation of PPARα (46).  Another example of ubiquitinated 
NRs is PR.  Inhibition of proteasome activity prevents receptor degradation and suppresses 
PR-dependent transcription through failed recruitment of RNA polymerase II (47).  BRCA1 
(breast cancer 1, early onset) inhibits the transcriptional activity of PR through its ubiquitin 
E3 ligase activity.  BRCA1 can regulate the ubiquitination and degradation of PR in the 
absence of hormones and have a direct effect on the cellular level of PR, which might explain 
why mutations of BRCA1 exert tissue specificity in preferentially elevating the risk of breast 
cancer (48).  
1.1.3.4 SUMOylation of NRs 
SUMO is the acronym of Small Ubiquitin-like Modifier.  Even though amino acid 
sequences of SUMO and ubiquitin are quite different, the structure of SUMO protein is 
similar to ubiquitin and the process of SUMOylation is comparable to ubiquitination.  
Recently, increasing numbers of NRs have been identified as SUMOylation substrates.  In 
general, SUMOylation is correlated with transcriptional repression.  The repression is 
achieved through recruitment of corepressor complexes.  Only in very few instances, 
SUMOylation leads to increased transcriptional activity. 
33 
 
AR is the first NR shown to be SUMOylated.  Mutation of SUMOylation sites in AR 
results in enhanced transcriptional activities of AR in reporter gene assays (49).  Recent 
studies using genome-wide gene expression analyses suggest that SUMOylation does not 
simply repress AR activities.   Sutinen et al. showed that SUMOylation regulated the 
interaction between AR and chromatin, and contributed to selective target gene expression 
(50).  Moreover, AR can directly regulate the expression of SENP1 (Sentrin-specific 
protease 1) through the androgen response element in SENP1 promoter (51).  SENP1 is a 
member of the sentrin protease family, which plays dual roles in SUMOylation process.  
SENPs can facilitate SUMO maturation and also deconjugate SUMO from substrates.  The 
mutual regulation between AR and SUMOylation pathway indicates the close involvement of 
SUMOylation in NR activities.  GR is also post-translationally modified by SUMO and the 
SUMOylation level is increased by the binding of glucocorticoids (52).  Depending on the 
site of SUMOylation, the transcriptional activities of GR can be either enhanced or repressed 
through alterations in the recruitment and/or activity of specific co-regulators (53, 54).  
Recent research indicates that SUMOylation regulates the activities of GR in a target 
locus-selective manner and affects genes both up- and down- regulated by GR (55).  
SUMOylation of PPARα in the hinge region and PPARγ in the AF-1 region block their 
transcriptional activities, possibly by promoting corepressors recruitment (56, 57).  
SUMOylation of PPARγ in the LBD results in its recruitment to promoters of inflammatory 
genes.  SUMOylated PPARγ inhibits the expression of inflammatory genes by preventing 
clearance of corepressor complexes (58).  With regard to PR, the SUMOylated receptor is 
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exceptionally stable and has repressed transcriptional activity, while deSUMOylated PR is 
rapidly downregulated and transcriptionally hyperactive (59). 
1.1.3.5 The Crosstalk between Different PTMs 
PTMs on NRs are more complex than discussed above.  NRs can also be modified by 
methylation, Neddylation, and many other PTMs.  Orchestration of these modifications is 
required for full control of NRs activities.  The effects of PTMs on NRs activities are also 
dependent on physiological conditions, cell and tissue types, and specific genes being 
regulated.  These complexities may explain how tissue- and gene-specific regulations are 
achieved in the same organism, by the same receptor protein and hormone. 
The crosstalk between different PTMs can be sequential.  The presence of one 
modification can lead to or facilitate another modification.  For example, both 
phosphorylation-dependent SUMOylation and phosphorylation-dependent ubiquitination have 
been identified (60, 61).  Heterologous SUMO2/3-ubiquitin chains have also been observed.  
It is suggested that SUMOylation by SUMO2/3 but not SUMO1 promotes ubiquitination and 
ubiquitination-dependent degradation by the proteasome (62).  A class of ubiquitin E3 
ligases, including RNF4 (RING finger protein 4), are identified as SUMO-target ubiquitin 
ligases, which are ubiquitin E3 ligases specifically recognize SUMOylated proteins to 
facilitate ubiquitination on SUMOylated proteins (63).  Heterologous SUMO2/3-ubiquitin 
chains play important physiological and pathophysiological roles.  One example is the 
regulation of NF-κB activity.  Under conditions of deficient SUMOylation, a delay in NF-κB 
dependent transcription is observed (64).  Another example involves acute promyelocytic 
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leukemia (APL).  Arsenic is used to treat APL patients, since it can promote the proteasomal 
degradation of PML (promyelocytic leukemia) protein and the oncogenic PML-RARα fusion 
protein.  Arsenic treatment first leads to increased SUMO2/3 modification of these proteins.  
RNF4, the SUMO-dependent ubiquitin E3 ligase, recognizes these SUMOylated proteins and 
targets these proteins for RNF4-mediated ubiquitination and degradation (65, 66).  Data 
generated in our laboratory indicate that the presence of SUMO proteins (both SUMO1 and 
SUMO3) increases not only the ubiquitination of PXR but also the global ubiquitination.  
Though the underlying mechanism and the biological function remain unclear, it is feasible 
that the modification by SUMO can facilitate the ubiquitination of different substrates.  
Future efforts to identify the SUMO-dependent ubiquitin E3 ligases involved in this process 
and then knockdown of the identified ligases will further confirm the hypothesis. 
In addition to sequential crosstalk, there is also spatial crosstalk among PTMs, like 
competition for the same site by different PTMs.  The competition for the same modification 
sites suggests mutual exclusivity of these modifications.  One instance is the competition 
between SUMO1 and ubiquitin for the same lysine in IκBα, which is an inhibitor for NF-κB.  
SUMOylation by SUMO1 inhibits the ubiquitination and degradation of IκBα, thus inhibits 
the activation of NF-κB pathway (67).  Besides the competition for the same amino acid, 
crosstalk among adjacent sites in the primary amino acid sequence or higher order structure of 
protein also exists.   For example, acetylation of FXR at K217 inhibits its SUMOylation at 
K277, partly by blocking the interaction with PIASy (protein inhibitors of activated STAT), 
which is the SUMO E3 ligase that promotes FXR SUMOylation (68).  
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However, the crosstalk between PTMs is much more complicated than discussed above.  
It is well-accepted that different forms of PTM interact with one another in a highly complex 
manner to control protein function.  One modification can also indirectly influence other 
modifications.  For instance, the ubiquitin conjugating enzyme E2-25K is inactivated by 
SUMOylation.  SUMOylation of E2-25K hampers its interaction with the upstream E1 
activating enzyme and inhibits ubiquitin thioester formation (69).  Another example is 
MDM2, which is the major ubiquitin E3 ligase that regulates the stability and activity of p53.  
MDM2 not only facilitates ubiquitination of other proteins, including p53 and AR, but also its 
self-ubiquitination.  SUMOylation of MDM2 prevents self-ubiquitination and hence, 
stabilizes MDM2 and increases its E3 ubiquitin ligase activity towards p53 (70, 71).  
Moreover, acetylation of MDM2 down-regulates its E3 ligase activity towards both p53 and 
Mdm2 itself (72).  Furthermore, SUMOylation of Psmd1, a subunit of the proteasomal 19S 
regulatory particles, can alter proteasome composition and function, and impact the 
degradation of proteasomal targets, thus increases the accumulation of ubiquitinated proteins 
(73).   
Different types of stresses can result in different sets of PTMs and lead to different 
activities of NRs.  The studies on crosstalk of PTMs on NRs have just begun to emerge.  
Targeting PTMs can be a novel way to treat NRs-related diseases.  Moreover, it should be 
noted that co-regulatory proteins of NRs can also be post-translationally modified, which 
represents another level in the regulation of NRs activities. 
1. 1. 4 Liver-enriched Nuclear Receptors and Inflammation 
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Inflammation is the body’s protective attempt to remove injurious stimuli, like foreign 
bacteria and viruses, and to initiate the healing process to restore tissue homeostasis.  Once 
stimuli are successfully removed from the body, acute inflammation should be resolved soon.  
The initiation of acute inflammation has beneficial effects to protect the body.  However, 
chronic inflammation is associated with many diseases.  Consequently, metabolic syndrome 
and related disorders including obesity, atherosclerosis, and diabetes are all related to 
inflammation.  Thus, it is of great importance to regulate the inflammatory response.  Many 
NRs have been shown to repress inflammation and immune responses through diverse 
mechanisms.  Glucocorticoids have been widely used for decades to treat inflammation 
related diseases.  The liver is the major organ of acute phase protein synthesis.  On the 
other hand, the liver is also the major organ for metabolism.  It is the obvious target tissue 
for integrating metabolic signaling and inflammation.  A number of publications indicate 
crucial roles of liver-enriched NRs in repressing inflammatory processes.  Liver X receptors 
(LXRs, NR1H), peroxisome proliferator activated receptors (PPARs, NR1C) and farnesoid X 
receptor (FXR, NR1H4) have all been shown to repress inflammation. 
LXRs inhibit the expression of inflammatory response genes through protein-protein 
interactions, where ligand bound LXRs become SUMOylated by SUMO2/3 and are recruited 
to inflammatory response gene promoters to inhibit the clearance of corepressors (74, 75).  
Other mechanisms have also been proposed.  Canavan et al. showed that in dendritic cells, 
activation of LXRs prevented the nuclear translocation of the p50 subunit of NF-κB, thus 
inhibiting NF-κB activities (76).  Li et al. showed that in macrophage, LXR activators 
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attenuated both DNA binding and transactivation potential of STAT1 (Signal Transducers and 
Activators of Transcription 1) in response to IFN-γ treatment (77).  
PPARs can attenuate inflammatory response through both direct and indirect 
mechanisms.  PPARα upregulates the expression of IκB, which tethers NF-κB in the 
cytoplasm and functions as a negative regulator of NF-κB (78).  The interleukin-1 receptor 
antagonist (IL-1Ra), an anti-inflammatory cytokine that inhibits the IL-1 signaling pathway, 
is a direct target gene of PPARα in the liver.  Through upregulating IL-1Ra level, activation 
of PPARα can decrease the activities of IL-1 signaling (79).  Via activating AMPK 
(AMP-activated protein kinase), PPARβ/δ can prevent ER stress, inflammation and insulin 
resistance in skeletal muscle cells (80).  PPARγ has been shown to prevent the removal of 
corepressor complexes from the promoter of inflammatory response genes to inhibit their 
expression (58).  
The anti-inflammatory effect of FXR is demonstrated by the fact that FXR null mice 
display strong hepatic inflammation.  Activation of FXR inhibits NF-κB-mediated hepatic 
inflammatory response but does not suppress NF-κB-activated anti-apoptotic genes in 
primary mouse hepatocytes.  It is suggested that FXR activation suppresses NF-κB 
transcriptional activity by decreasing the binding between NF-κB and DNA sequences (81).  
The loss of FXR also leads to exacerbated inflammation in rodent models of colon 
inflammation.  Consistent with the findings, the expression level of FXR is reduced in both 
patients with Crohn’s disease and rodent models of colitis.  The protective role for FXR is 
further confirmed by the fact that activation of FXR by ligand treatment protects against the 
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development of colitis in wild type mice but not in FXR-KO mice (82).  The underlying 
mechanism is suggested to involve SUMOylation of FXR, since mutation of the potential 
SUMOylation site impairs the transrepression activity of FXR (82). 
In addition to the NRs discussed above, anti-inflammatory properties have also been 
found for other liver-enriched NRs.  Small heterodimer partner (SHP, NR0B2) has been 
suggested to be an intrinsic negative regulator of Toll-like receptor (TLR)-triggered 
inflammatory response, acting as both a repressor of the NF-κB subunit p65 and an inhibitor 
of ubiquitination of TRAF6 (83).  Moreover, SUMOylated LRH1 (liver receptor homolog-1, 
NR5A2) can prevent the removal of co-repressor complexes from the promoter of 
inflammatory response genes (84).   
 
1.2. Pregnane X Receptor 
1.2.1 General Remarks 
Discovered in 1998 based on the structural homology to other NRs, PXR gets its name 
from the activation by pregnane (21-carbon or C21) steroids (85).  It was considered as an 
orphan nuclear receptor until xenobiotics were identified as PXR ligands.  Nowadays, PXR 
is well-known as the xenobiotic sensor to increase the metabolism and clearance of drugs and 
xenobiotics from the body, and protect the body from potential toxic insults.  It is a member 
of the NR1I subfamily, which also contains vitamin D receptor (VDR, NR1I1) and 
constitutive androstane receptor (CAR, NR1I3).  PXR is most closely related to VDR in the 
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NR family, sharing 64% identity in the DBD and 39% in the LBD (86).  However, CAR has 
the most overlapping ligand specificity and function with PXR.  With overlapping but 
distinct functions, these NRs work both individually and collaboratively to regulate the 
metabolism and elimination of both endogenous and exogenous compounds (87). 
PXR forms a heterodimer with RXRα and binds to PXR response elements to regulate 
the expression of its target genes.  Consistent with its function in xenobiotic clearance, PXR 
is highly expressed in the major detoxifying organs such as liver and intestinal tract, but low 
levels of expression can also be found in other tissues, like kidney and stomach.  PXR is 
conserved through evolution within the animal world and has been cloned and functionally 
expressed from zebrafish, frog, chicken, and multiple mammalian species.   
The most remarkable characteristic of PXR is the promiscuity with respect to ligands.  
PXR can be activated by xenobiotics, steroid hormones, and bile salts among many 
compounds with diverse structures.  In point of fact, PXR has the broadest ligand specificity 
among the NR family.  The promiscuity of PXR ligands is related to the unique binding 
capability of its LBD.  The ligand binding cavity of PXR is large, smooth, and hydrophobic, 
unlike ‘typical’ NR LBDs, which compact ligand-binding cavities to the approximate shape 
of specific ligands (88).  The PXR ligand-binding cavity also shows considerable flexibility 
to accommodate the binding of structurally-diverse ligands.  One interesting fact is that just 
like PXR, proteins encoded by PXR target genes, like CYP3A4 (Cytochrome P450 3A4) and 
P-glycoprotein, also show substrate promiscuity, and can metabolize or bind to a diverse class 
of chemically unrelated compounds. 
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Besides ligand promiscuity, another important feature of PXR is the species difference.  
Ligands for PXR are quite diverse among different species.  For example, PCN 
(Pregnenolone 16α-carbonitrile) is a strong murine PXR agonist, but it has little effect on 
human PXR.  Rifampicin is a potent human PXR ligand that has less effect on murine PXR.  
The sequence divergence in PXR LBD among different species is suggested to be responsible 
for the species difference.  The sequence similarities of PXR LBD across species are the 
lowest in the NR family, with other NRs at least 10-15% higher (11).  Besides species 
difference in ligands, signaling pathways can also have different regulatory effects on PXR 
function in different species.  For instance, while activation of the cyclic AMP-dependent 
protein kinase signaling pathway increases PXR-mediated gene activation in mouse 
hepatocytes, the same signaling pathway represses PXR-mediated gene activation in rat and 
human hepatocytes (89).  It is suggested that the species difference of PXR is to 
accommodate the needs of different species.  Since different species encounter different 
compounds, the profiles of xenobiotics that the zebrafish would encounter are definitely not 
the same as rodents would encounter.   
1.2.2 PXR in Xenobiotic Metabolism and Clearance 
PXR activation protects animals against potentially toxic compounds by facilitating their 
metabolism and clearance (90).  Upon activation by its ligands, PXR up-regulates the 
expression of genes that encode detoxification enzymes and transporters.  The protective 
role of PXR can be proved by the findings that after being challenged with toxic compounds 
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such as lithocholic acid (LCA), PXR-KO mice display much severe liver damage compare to 
wild type mice (91).  
Activation of PXR leads to increased expression of phase I (oxidation) and phase II 
(conjugation) metabolizing enzymes and phase III transporters to enhance the metabolism and 
transport of a broad range of endogenous and exogenous compounds.  The phase I 
metabolizing enzymes facilitate the oxidative metabolism of endogenous substances and 
xenobiotics.  Cytochrome P450 enzymes convert lipophilic compounds into more 
hydrophilic products, making them ready for further biotransformation by phase II enzymes 
(92).  CYP3A4, one of the well-characterized PXR target genes, is the most abundant CYP 
expressed in human liver.  While PXR has a broad ligand specificity, CYP3A4 also has a 
remarkably broad substrate specificity, and metabolizes more than half of the pharmaceuticals 
on the market, which makes PXR activation closely related to adverse drug events (93).   
Through conjugation, phase II drug metabolism enzymes greatly enhance the water 
solubility of compounds containing conjugatable groups that are either present on the 
compounds or introduced by phase I metabolizing enzymes, and promote their excretion.  
Activation of PXR can increase the expression of phase II drug metabolism enzymes like 
uridine-5′-diphosphate glucuronosyl transferase (UGT), sulfotransferase (SULT), and 
glutathione S-transferase (GST) to facilitate the excretion of toxic compounds (94-97). 
In addition to its role in regulating metabolism enzymes, PXR also regulates drug 
transporters for efflux and uptake of endogenous and exogenous compounds (98).  Some 
examples of drug transporters that are regulated by PXR are MDR1 (multidrug resistance 
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protein 1), MRPs (multidrug resistance proteins), and OATP2 (organic anion transporting 
protein 2). (99, 100).  Up-regulation of these proteins by PXR provides a critical determinant 
of the bioavailability of drugs in the body.  PXR activation is suggested to be responsible for 
drug resistance in cancer cells. 
PXR activation protects the body from exposure to toxic compounds.  However, 
activation of PXR is not without a risk.  As a key regulator of drug metabolism and 
clearance, unexpected or abnormal activation of PXR may lead to adverse drug-drug and 
disease-drug interactions, which are major clinical problems increasing not only the medical 
costs but also morbidity and mortality.  Altered levels of CYP3A4 and MDR1 can 
significantly affect the therapeutic response of a variety of administered drugs, and can cause 
serious drug-drug interactions (101).  PXR-dependent adverse drug-drug interactions may be 
avoided if suitable PXR antagonists are widely available.   
1.2.3 Other Biological and Pathophysiological Functions of PXR 
1.2.3.1 Glucose Homeostasis 
Hepatic gluconeogenesis is required for survival during prolonged fasting or starvation.  
Activation of PXR has been suggested to suppress gluconeogenesis, mostly through 
protein-protein interactions.  PXR can repress glucagon-activated transcription of G6Pase 
(glucose-6-phosphatase) and PEPCK (phosphoenolpyruvate carboxykinase).  Both enzymes 
play key roles in the homeostasis of blood glucose level.  PXR mediated suppression is 
achieved through the interaction with CREB [CRE (cAMP-response element)-binding 
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protein], which is the transcription factor that activates the transcription of G6Pase and 
PEPCK.  PXR binds directly to CREB and this binding prevents the interaction between 
CREB and CRE (102).  FOXO1 (Forkhead box protein O1) is another activator of 
gluconeogenic genes.  PXR directly interacts with FOXO1 to prevent its binding to insulin 
response sequence (103).  The interaction between PXR and FOXO1 is enhanced by PXR 
ligand.  Through the inhibition of FOXO1, PXR suppresses gluconeogenesis.  HNF-4 is 
another activator for G6Pase and PEPCK expression.  Bhalla et al. suggested that 
ligand-activated PXR attenuated HNF-4 signaling by competing for the coactivator PGC-1 
(Peroxisome Proliferator Activated Receptor Gamma Co-activator 1), and resulted in 
repressed expression of G6Pase and PEPCK (104).  In support of this suggestion, PCN 
treatment decreases blood glucose levels in fasting wild-type, but not in PXR-KO mice (105).   
1.2.3.2 PXR in Lipid Homeostasis 
Both genetic (using the VP-hPXR transgene) and pharmacological (using the PXR 
agonist) activation of PXR have been shown to induce hepatic steatosis, suggesting the 
regulatory role of PXR in lipid homeostasis (106-108).  Activation of PXR can increase de 
novo lipogenesis, increase fatty acid uptake, and at the same time, inhibit fatty acid 
β-oxidation.  All of these processes contribute to the pathogenesis of steatosis.   
S14 protein can transduce hormone-related and nutrient-related signals to genes involved 
in lipid metabolism and plays an important role in the induction of lipogenic enzymes (109, 
110).  By regulating the expression of S14 (thyroid hormone–responsive SPOT14 homolog), 
PXR contributes to de novo lipogenesis (111).  PXR can also directly bind to CD36 
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promoter to regulate CD36 expression, which is the transporter that transports free fatty acids 
into cells (112).  Increased expression of CD36 leads to enhanced fatty acids uptake and 
hepatic lipid accumulation.  β-oxidation is an important step of fatty acid catabolism.  The 
expression of PPARα and thiolase, both of which regulate β-oxidation, is decreased by PXR, 
suggesting that activation of PXR suppresses β-oxidation (108).  Cpt1a (carnitine 
palmitoyltransferase 1A) and Hmgcs2 (mitochondrial 3-hydroxy-3-methylglutarate-CoA 
synthase 2) are two enzymes regulating β-oxidation and ketogenesis.  FoxA2 is the key 
regulatory factor that activates the transcription of these genes in fasting mouse liver (113).  
PXR could bind to FoxA2 and prevent the binding of FoxA2 to the promoter of target genes, 
thus inhibiting the expression of Cpt1a and Hmgcs2 (105).  By simultaneously increasing de 
novo lipogenesis, increasing fatty acid uptake and inhibiting fatty acid β-oxidation, PXR 
contributes to the accumulation of lipids in cells.   
1.2.3.3 PXR and Bile Acids Homeostasis 
The conversion of cholesterol to bile acids occurs exclusively in hepatocytes.  
Cholesterol 7-α-hydroxylase, also known as cytochrome P450 7A1 (CYP7A1), regulates the 
first and rate limiting step in bile acids synthesis.  PXR together with many NRs tightly 
control the level of bile acids in the body through a complex network.  While bile acids are 
endogenous ligands for FXR, PXR can also be activated by bile acids (91, 114).  Upon 
activation, PXR induces the expression of its target genes, including CYP3A and OATP2.  
While CYP3A can catalyze side-chain hydroxylation to make bile acids more hydrophilic, 
and promote their excretion, OATP2 facilitates the transport of bile acids, increasing the 
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uptake and excretion of them.  Besides positively regulating gene expression, activation of 
PXR also inhibits the expression of CYP7A1 through its interaction with HNF-4α.  HNF-4α 
is a positive regulator of CYP7A1 expression.  The interaction with PXR disrupts 
HNF-4α/PGC-1α interaction and reduces the transcriptional activity of CYP7A1 gene 
promoter (115).  Through the regulation of gene expression, PXR simultaneously regulates 
the biosynthesis, transport, and metabolism of bile acids, indicating that PXR serves as a 
physiological sensor not only for xenobiotics but also for bile acids.  Because of this, PXR 
has been proposed as a therapeutic target for the treatment of cholestasis (116).  
1.2.3.4 PXR in Vitamin D Metabolism and Bone Mineral Homeostasis 
It has been known for decades that long-term treatment with PXR activators can 
decrease serum vitamin D levels and bone mineral density, leading to drug-induced 
osteomalacia  (117, 118).  Calcium is a major component in bone development and 
maintenance, whose absorption and excretion are regulated by vitamin D.  Vitamin 
D3 24-hydroxylase (CYP24A1) converts the active 1α, 25-dihydroxyvitamin D3 (1, 25(OH) 
2D3) into an inactive metabolite, acting as a feedback regulatory factor in calcium 
homeostasis.  Activation of PXR has been suggested to both activate and repress CYP24A1 
expression (119, 120).   It has been demonstrated that in the absence of vitamin D3, PXR 
could activate CYP24A1 promoter by directly binding to the VDRE (Vitamin D response 
element) region.  However, in the presence of vitamin D3, PXR indirectly bound to the 
VDRE region and locked SMRT onto VDR to repress CYP24A1 promoter.  Moreover, 
CYP3A4, whose expression is regulated by PXR, also metabolizes and inactivates 1α, 
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25-dihydroxyvitamin D3 (1, 25(OH) 2D3) (121, 122).  Even though the affinity and 
efficiency of CYP3A4 to metabolize 1α, 25-dihydroxyvitamin D3 (1, 25(OH) 2D3) is lower 
than CYP24A1, the abundant expression level of CYP3A4 might make it the dominant player 
in 1α, 25-dihydroxyvitamin D3 (1, 25(OH) 2D3) metabolism in the liver.   
1.2.3.5 PXR and Cancer Development 
 PXR is over-expressed in many cancer cells (123-125).  The increased PXR activity 
leads to enhanced expression of drug metabolism enzymes and drug transporters, like 
CYP3A4 and P-glycoprotein, which increase drug clearance and decrease the exposure of 
cancer cells to anticancer drugs, thus leading to drug resistance.  In addition to drug 
metabolism and clearance, PXR also regulates tumor proliferation and metastasis as well as 
apoptotic/anti-apoptotic processes.  PXR is well-known to regulate hepatocytes 
proliferation and is required for normal progression of liver regeneration (126-128).  
Besides hepatocytes, PXR also regulates cell growth in different cancer tissues (129, 130).  
Additionally, PXR activation induces metastasis of cancer cells.  It has been shown that 
activated PXR elicits p38 phosphorylation, which can lead to cell migration (131).  PXR 
also induces metastasis of the primary human colon cancer tissues xenografted into 
immune-deficient mice.  Moreover, PXR expression is reported to be higher in invasive 
stage than in early stage of breast cancer patients (132, 133).  The activation of PXR can 
also increase cell viability and repress drug-induced apoptosis.  PXR agonists can increase 
the expression of Bcl-2 and Bcl-xL, two apoptosis inhibitors, at both mRNA and protein 
levels in human and rat hepatocytes (134).  Besides hepatocytes, PXR also inhibits 
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apoptosis in non-hepatic cancers, like colon cancer (135).  However, there are also many 
incidents in which PXR induces cell apoptosis, suggesting that PXR-regulated cell 
proliferation and apoptosis are tissue and cell/context-specific (136, 137).   
Because of the roles of PXR in cancer development and progression, antagonists of PXR 
has been proposed to improve the bioavailability of anti-cancer drugs and to reverse 
PXR-mediated cancer drug resistance and tumor growth (138).  Controversy still remains for 
the roles of PXR in cancer development, so further studies that decipher the function of PXR 
in different cancers will be useful to therapeutically target PXR in PXR expressing cancers. 
1.2.3.6. PXR and Inflammation 
Long before the identification of PXR, it has been noticed that treatment of rifampicin, 
later known as a prototypical human PXR ligand, can suppress humoral and cellular 
immunological response (139).  The expression levels of inflammatory cytokines are higher 
in hepatocytes from PXR-KO mice compared to wild type mice.  Activation of PXR 
decreases the expression of inflammatory cytokines in isolated wild type hepatocytes but not 
in PXR-KO hepatocytes, suggesting PXR-dependent repression in the inflammatory response 
(140).   
Besides in hepatocytes, similar effects were also observed in the intestine.  PXR has 
been suggested as a therapeutic target to treat inflammatory bowel disease.  Through 
inhibition of NF-κB target gene expression, PXR activation ameliorates dextran sulfate 
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sodium (DSS)-induced inflammatory bowel disease (141).  Some drugs that have been used 
to treat inflammatory bowel diseases later turned out to be PXR ligands.   
While the anti-inflammation property of PXR has been known for decades, the 
underlying mechanism is still vague.  Our previous publication demonstrates that 
SUMOylation of PXR is essential for the repression of inflammatory genes (140).  The role 
of PXR and SUMOylation in inflammation will be discussed in detail in chapter 3. 
Humans are constantly exposed to xenobiotics that activate PXR.  From the previous 
discussion, it is clear that PXR regulates both xenobiotic and endobiotic homeostasis.  
Besides the pathophysiological pathways discussed above, PXR also has regulatory effects on 
inflammation, bilirubin detoxification, steroid hormones and vitamin metabolism, among 
many more to be discovered.  Therefore, PXR activation has important implication in many 
pathophysiological conditions.  Recent studies indicate that activation of PXR is beneficial 
in the treatment of many diseases, like cholestasis, inflammatory liver disease and 
inflammatory bowel diseases, suggesting the potential of PXR as a therapeutic target.  The 
plethora roles of PXR also raise the questions like how PXR is regulated to coordinate 
different biological pathways, how PXR function is balanced within these diverse pathways.  
Post-translational modifications such as phosphorylation have been shown to modulate the 
activity of many NRs, including PXR, and constitute an important mechanism for crosstalk 
between signaling pathways and NR-mediated gene expression.  In the following chapters, 
some post-translational modifications of PXR and their effects on PXR function will be 
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Chapter 2: Identification of Novel PXR Interacting Proteins using Yeast 
Two Hybrid System 
As discussed in chapter 1, PXR is an important regulator of xenobiotic metabolism and 
clearance.  Through protein-protein interactions, PXR also regulates biological processes 
like glucose homeostasis, lipid homeostasis, and bile acid homeostasis.  Since 
protein-protein interactions control the function of both PXR and its interacting proteins, the 
identification of novel PXR interacting proteins can lead to better understanding of the 
function and regulation of this important nuclear receptor.  In this chapter, yeast two hybrid 
system was used to explore novel PXR interacting proteins in a human liver cDNA library.   
2.1 Introduction to yeast two hybrid system 
The yeast two hybrid system, developed by Fields and Song in 1989, is a widely-used 
method to study protein-protein interactions (1).  This method is based on the properties of 
GAL4, which is a transcription factor that regulates the expression of enzymes for galactose 
metabolism in yeast.  Like most transcription factors, there are two functional domains in 
GAL4: an N terminal DNA binding domain (DBD) and a C terminal activation domain (AD).  
The DBD can bind to the promoter of target genes in a sequence-dependent manner, but it 
cannot activate gene expression.  The AD has activating regions, but it also cannot activate 
gene expression on its own, since it fails to bind to DNA.  One important feature of 
transcription factors is that once the DBD and AD are in close proximity, even though they 
are not covalently attached to each other, a functional transcription factor can be reconstituted.  
Based on this characteristic, in the yeast two-hybrid system, one protein is fused to the DBD 
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of GAL4 (bait) and another protein is fused to the AD of GAL4 (prey).  If these two proteins 
interact with each other, they will bring the DBD and AD together, thus restoring the function 
of GAL4, and this leads to the expression of one or more reporter genes in engineered yeast 
strains (illustrated in Fig. 2-1).  
In the yeast two-hybrid system, the interactions between proteins are reflected by the 
expression of reporter genes.  Fields and Song introduced GAL1-lacZ fusion gene into a 
GAL4/GAL80 null yeast strain (1).  The GAL1 promoter contains DNA sequences to which 
the GAL4 protein binds.  GAL80 is a negative regulator of GAL4, whose regulatory effect is 
dependent on galactose availability.  In the absence of galactose, GAL80 binds to GAL4 and 
keeps it inactivated.  When galactose is present, the inhibition of GAL80 on GAL4 is 
relieved, leading to the expression of GAL4 target genes (2).  Since in engineered yeast 
strains, endogenous GAL4 and GAL80 are genetically deleted, the expression of lacZ solely 
depends on the function of exogenous GAL4: the GAL4 DBD and AD which are fused to the 
proteins of interest.  By detecting the activity of β-galactosidase, protein-protein interactions 
can be examined.  Since the invention of yeast two-hybrid system, numerous reporter genes 
and engineered yeast strains have been developed.  In our experiment, we employed strain 
Y153, which is also a GAL4/GAL80 null yeast strain (3).  It contains the GAL1-lacZ fusion 
gene introduced earlier, as well as a HIS3 reporter gene, which is also under the control of the 
GAL1 promoter.  HIS3 encodes imidazoleglycerol phosphate (IGP) dehydratase, an 
indispensable enzyme for histidine biosynthesis.  Theoretically, without protein-protein 










Figure 2-1.  Schematic Representation of Yeast Two Hybrid System.  (A) In the yeast 
two hybrid system, protein X is fused to the DNA binding domain (DBD) and this fusion 
protein is known as ‘bait’.  Protein Y is fused to activation domain (AD) and this fusion 
protein is termed ‘prey’.  If protein X and Y do not interact with each other, DBD and AD 
would be isolated from each other, the transcription of reporter gene cannot be initiated.  (B) 
If these two proteins interact with each other, they will bring the DBD and AD together, and 
restore the function of GAL4, leading to the expression of one or more reporter genes in 













histidine), since the essential amino acid cannot be produced without IGP dehydratase.  
However, the HIS3 reporter is relatively “leaky” and residual expression of the reporter is 
enough for yeast cells to grow even in the dropout medium.  In order to reduce false positive 
results, 3-aminotriazole (3-AT), an inhibitor of IGP dehydratase, is added to the medium to 
increase the stringency of the system.  Y153 also contains auxotrophic mutations for 
tryptophan and leucine, which can be complemented by plasmids encoding prey and bait 
proteins, and serves as an extra way to eliminate background growth.  
In this chapter, we try to identify novel interacting proteins for PXR by utilizing the 
yeast two hybrid system to screen a human liver cDNA library.  After the potential PXR 
interacting proteins were identified, the results were further confirmed using another yeast 
stain Y190, and also in mammalian cells using a mammalian two hybrid system.  
 
2.2 Materials and Methods 
Plasmids.  Human PXR-LBD was generated by PCR from pSG5-hPXR using primers 
5’-GAC GCC ATG GAG GGC ATG AAG AAG GAG ATG ATC-3’ and 5’-GAC GCC 
GGA TCC CTA GCT ACC TGT GAT GCC GAA C-3’ designed with NcoI and BamHI sites.  
The PCR product was subcloned in frame into GAL4 DNA binding domain vector pGBKT7 
(Clontech) using NcoI and BamHI sites.  pACT2-hPXR-LBD was subcloned from 
pGBKT7-hPXR-LBD using NcoI and BamHI sites.  For pGBKT7-LBP4, LBP4 was excised 
from pACT2-LBP-4 with BglII and inserted into pGBKT7 multiple cloning site (MCS) using 
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BamHI site.  To build pM-LBP-4, LBP-4 was excised from pACT2 LBP-4 with BglII and 
then excised LBP-4 fragment was inserted into pM MCS using BamHI site.  BamHI sites 
were introduced to SUG1 using primers  5’-GAC GGC GGG ATC CGT GGA CCA GAG 
CAG ATG GAG CTG GAG-3’ and  5’-GAC GGC GGA TCC TCA TTA TTG GAG AGA 
TAC ACA CAA AGG-3’, PCR product was subcloned into pM BamHI site to produce 
pM-SUG1. SMRT-ID2 was excised from pACT2-LBP227/SMRT-ID2 with BglII and 
inserted into pM BamHI site. The validity of all constructs was confirmed by sequencing. 
Yeast Transformation, Cell Lysis and Western Blotting.  Yeast were transformed 
using the lithium acetate (LiAc)-mediated method.  In brief, both plasmid and carrier DNA 
were mixed with yeast competent cells with PEG/LiAc.  After incubation, DMSO was added 
to the cell/DNA mixture before heat shock.  After heat shock, cells were collected by 
centrifugation and resuspended in 1×TE buffer (10mM Tris, pH 7.5, 1mM EDTA) and plated 
on appropriate selective plates.  After colonies formed, a single colony was expanded in 
appropriate selective medium.  After growth, yeast cells were harvested in complete 
cracking buffer (8M Urea, 5% SDS, 40 mM Tris pH 6.8, 0.1 mM EDTA, 0.4mg/ml 
Bromophenol blue, adding 1% β-mercaptoethanol, 1×PIC before use) with glass beads. 
Whole cell lysates were subjected to SDS-PAGE and the gel was transferred to 
polyvinylidene difluoride membrane with subsequent western blot analysis using an anti-PXR 
antibody (sc-48340, Santa Cruz). 
Yeast Two Hybrid Analysis.  Y153 yeast cells were transformed with 
pGBKT7-hPXR-LBD construct encoding bait protein to screen a human liver cDNA library 
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constructed in vector pACT2 (Clontech).  Yeast cells were plated on selection plates lacking 
histidine, tryptophan and leucine and in the presence of 25mM 3-Aminotriazole (3-AT).  
Primary positive colonies were tested for LacZ expression by colony-lift filter assay.  Prey 
plasmids of positive colonies were recovered and sequenced.  The identities of the encoded 
putative interacting proteins were determined by data base search (Blastx). 
Quantitative β-galactosidase Assay.  After growing overnight in the selection medium, 
yeast cells were transferred to complete medium to grow until the OD at 600 nm reached 
0.5-0.8.  Cells were washed and resuspended in Z-buffer (60mM Na2HPO4, 60mM NaH2PO4, 
10mM KCl, 1mM MgSO4, pH 7.0) and then subjected to freeze (liquid nitrogen) and thaw 
(37 °C water bath) cycle to lyse cells.  Z-buffer containing 4mg/ml 
o-nitrophenyl-β-D-galactopyranoside was applied to cell lysates.  After the yellow color 
developed, reaction tubes were centrifuged to get the supernatant and subjected to 
measurement at an OD of 420 nm.  Assay results were normalized to the cellular absorbance 
value. 
β-galactosidase units were calculated using the formula: 
β-galactosidase units=1000×OD420/(t×V×OD600) 
t=elapsed time of incubation 
V=0.1ml×concentration factor 
OD600= A600 of 1ml culture 
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Transient Transfection and Mammalian Two Hybrid System.  CV-1 cells were 
plated in 96-well plates at 7000 cells per well.  The next day, the cells were transfected with 
the indicated plasmids using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions.  24 hours post-transfection, cells were treated for another 24 
hours with either vehicle or 10μM rifampicin.  Luciferase activities were determined using a 
standard luciferase assay system (Promega).  Luciferase assay results were normalized by 
β-galactosidase activities, which were determined by o-nitrophenyl-β-D-galactopyranoside 
assay.   
 
2.3 Results 
The Identification of Novel PXR Interacting Proteins in Yeast Two Hybrid System 
in Y153 Cells.  Before the screening, the expression of bait protein, 
GAL4-DBD-hPXR-LBD, was confirmed in yeast cells (shown in Fig.2-2).  It was further 
confirmed that the fusion protein did not autonomously transactivate the reporter genes.  
After these confirmations, Y153 cells were co-transformed with the construct encoding bait 
protein and the commercially available human liver cDNA library constructed in pACT2 
vector (Clontech).  After yeast colonies were formed on dropout (-Trp-Leu-His) plates 
supplied with 25mM3-AT, colonies were lifted and subjected to the X-gal test.  The 
interaction was monitored by the appearance of blue color.  Around 6 million colonies were 
screened and the colonies were named as LBPs (PXR-LBD-binding Proteins).  The 





Figure 2-2.  Expression of GAL4-DBD-hPXR-LBD in Y153 Cells.  Y153 cells were 
transformed with pGBKT7-hPXR-LBD expression vector.  After the colonies were formed, 
one single colony was picked and inoculated in tryptophan dropout medium.  
Non-transformed Y153 cells were grew on YPD plate and inoculated in YPD medium as 
control.  After growth, yeast cells were harvested in complete cracking buffer.  Whole cell 
lysates were subjected to SDS-PAGE and subsequent western blot analysis using an anti-PXR 
















Among all the colonies, 8 positive ones were chosen for further study.  The plasmids 
harbored by positive yeast colonies were rescued using E. coli, and then transformed back to 
Y153 yeast cells together with pGBKT7-hPXR-LBD to further confirm the interaction.  
There were two false positives.  The others were subjected to sequencing and the identities 
of the encoded putative interacting proteins were determined by data base search (Blastx) and 
were listed in Table 2-1.  Among them, SUG-1, SHP, and NCoR2/SMRT (hereinafter, 
SMRT) are proteins which have already been recognized to interact with PXR (4-6).  The 
identification of known PXR interacting proteins lends credit to the validity of our screening.  
For the remaining two proteins, stromal cell derived factor 4 (SDF4) is localized in the Golgi 
lumen (7), the subcellular compartment where PXR is believed not to localize under normal 
circumstances.  Therefore, in the following experiments, we primarily focused on LBP-4.  
LBP-4 is a fragment of the protein p0071, which is a member of Armadillo (ARM) 
repeat-containing proteins.   
Confirmation of the Interaction Between hPXR-LBD and LBP-4 in Yeast Cells.  
Utilizing Y153 yeast cells, LBP-4 was identified as a potential hPXR-LBD interacting protein.  
To test whether this interaction was specific to hPXR-LBD, other bait protein constructs 
encoding NRs like Farnesoid X Receptor-ligand binding domain (FXR-LBD), Retinoid X 
Receptor α-ligand binding domain (RXRα-LBD) and other constructs encoding non-related 
bait proteins like O-acetyltransferase-related protein (OAT1) and organic cation transporter 1 
(OCTN1) were employed to test their interactions with LBP-4.  Among all these bait 
proteins, LBP-4 only interacted with PXR-LBD (as shown in Fig. 2-4).  This indicates that 
the interaction between LBP-4 and hPXR-LBD is restricted between LBP-4 and PXR but 
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Table 2-1.  Identities of the Identified hPXR-LBD Interacting Proteins from Yeast Two 
Hybrid Screening in Y153 Cells. 
Number  Identity 
LBP-0  SDF-4 Stromal Cell Derived Factor 4 
LBP-1 SUG-1 Suppressor for Gal 1 
LBP-4 p0071  
LBP-22 SHP Small Heterodimer Partner 
LBP-226 hypothetical protein   
LBP-227 NCoR2/SMRT Nuclear Receptor Co-repressor 2/ 
Silencing Mediator of Retinoic 
Acid and Thyroid Hormone 











Figure 2-4.  Interaction between LBP-4 and Other Bait Proteins in Y153 Cells.  Y153 
yeast cells harboring only prey plasmid (pACT2-LBP-4) were grew on Leu drop-out plates.  
Y153 yeast cells transformed with both prey (pACT2-LBP-4) and bait plasmids (as indicated 
in the figure) were grew on double drop-out (-Trp-Leu) plates.  The colonies were lifted and 
subjected to the X-gal test and the interaction was monitored through the appearance of the 




not other NRs.  To further confirm these results from Y153 cells, a different yeast strain, 
Y190, was utilized.  In Y190 cells, LBP-4 also interacted with hPXR-LBD but not with 
other testing proteins, consistent with what has been found in Y153 cells (Fig. 2-5).  Besides 
changing yeast strains, another way to circumvent false positive interactions is to swap bait 
and prey in the system (8).  In order to do that, LBP-4 was subcloned into pGBKT7 vector 
and hPXR-LBD was subcloned into pACT2 vector.  After protein expression was verified 
(data not shown), these two new constructs were co-transformed into Y190 cells and the blue 
colonies formed after the colony-lift filter assay indicated that LBP-4 still interacted with 
hPXR-LBD (Fig. 2-6).  While the X-gal test is only qualitative, we further employed another 
quantitative method, quantitativeβ-galactosidase assay.  As shown in Fig.2-7, among all the 
proteins tested, fold induction for the interaction between LBP-4 and hPXR-LBD was the 
highest.  
Confirmation of the Interaction Between hPXR-LBD and Novel PXR Interacting 
Proteins in Mammalian Cells.  To overcome the differences between yeast and mammalian 
cells, the mammalian two hybrid system was also utilized to confirm the interaction between 
PXR interacting proteins and hPXR-LBD.  The principle underlying the mammalian two 
hybrid system is quite similar to the yeast two hybrid system, but this system allows us to 
detect the interaction in mammalian cells by utilizing a mammalian reporter gene (Fig.2-8A).  
LBP-4, SUG1, SMRT-ID2 and SHP were subcloned into a pM vector from pACT2 vector to 
generate the fusion protein of PXR interacting proteins and GAL4 DBD.  Unfortunately, 
even though sequencing showed that the reading frame of pM-SHP was correct, the fusion 





Figure 2-5.  Interaction between LBP4 and hPXR-LBD in Y190 Cells.  Y190 yeast 
cells harboring only bait plasmids (as indicated in the figure) were plated on Leu drop-out 
plates.  Y190 yeast cells harboring both prey (pACT2-LBP-4) and bait plasmids (as 
indicated in the figures) were plated on double drop-out plates (-Trp-Leu).  The colonies 
were lifted and subjected to the X-gal test. The interaction was monitored through the 





Figure 2-6.  Interaction between hPXR-LBD and LBP-4 in Y190 Cells After the Bait 
and Prey Were Swapped.  LBP-4 was subcloned into pGBKT7 vector and hPXR-LBD was 
subcloned into pACT2 vector.  The constructs were transformed into Y190 yeast cells as 






Figure 2-7.  Quantitative Analysis of the Interactions between PXR and PXR 
Interacting Proteins.  The strength of the interaction between PXR and cofactors was 
measured in the yeast two hybrid system.  Different plasmids (as indicated in the figure) 
were transformed into the yeast strain Y190.  Quantitative analysis of β-galactosidase 
activity was performed using a liquid β-galactosidase assay.  All the cofactors are in pACT2 















Figure 2-8.  Interaction between hPXR-LBD and PXR Interacting Proteins in 
Mammalian Cells.  (A) Schematic representation of mammalian two hybrid system.  
Cells were transfected with pFR-Luc, a 5xGAL4 binding element–luciferase reporter gene, 
and plasmids encoding VP16-PXR and GAL4 DBD fused to different LBPs.  The 
interaction between LBPs and hPXR-LBD will lead to the expression of the reporter gene.  
(B) After transfection with indicated plasmids, cells were treated with 10 μM rifampicin for 
24h before luciferase and β-galactosidase activities were measured.  The transfection 
efficiency was normalized against the β-galactosidase activity from the cotransfected 
SV-β-gal.  Results shown are fold induction over vehicle treated reporter only group and 





could not further study the interaction between PXR and SHP in mammalian cells.  For the 
other DBD-PXR interacting proteins, they were co-transfected with VP16-AD-PXR into 
CV-1 cells.  Consistent with the data generated from yeast, LBP-4, SUG-1, SMRT-ID2 all 
interacted with PXR in the CV-1 cells.  The interaction between PXR interacting proteins 
and hPXR-LBD was affected by treatment with PXR ligand (Fig.2-8B).  For LBP-4, the 
interaction increased after ligand treatment, while for SUG-1, the interaction decreased after 
the same treatment.  The interaction between PXR and SMRT-ID2 slightly decreased after 
rifampicin treatment, but the difference was not statistically significant.  
 
2.4 Discussion  
In this chapter, the yeast two hybrid system was used to explore new interacting proteins 
for hPXR-LBD.  The identification of known PXR interacting proteins, SUG-1, SHP, and 
SMRT, confirmed the validity of the screening.  From the screening, p0071 was also 
identified as a potentially novel interacting protein for PXR.  The interaction between PXR 
and the identified interacting proteins will be discussed below. 
2.4.1 The Interaction between PXR and p0071. 
p0071 is a member of the ARM repeat-containing protein family.  This protein family 
is characterized by containing the tandem ARM repeats.  The members in this family can be 
divided into three subfamilies referred to by representative members: β-catenin, p120, and 
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plakophilins (As shown in Fig. 2-9A).  LBP-4 is a fragment of p0071 containing the first 5 
ARM repeats and part of the sixth ARM repeat of p0071 (Shown in Fig. 2-9B).   
ARM repeat-containing proteins are well-known for their structural roles at anchoring 
junctions, which is one type of cell-cell junctions.  There are two main categories of 
anchoring junctions: adherens junctions and desmosomes.  These two anchoring junctions 
share a similar structure and are distinguished primarily on the filament system to which they 
attach.  In most cases, members of the β-catenin and p120 subfamilies assemble into 
actin-associated adherens junctions, whereas the plakophilins assemble into intermediated 
filament-based desmosomes.  In certain, conditions, some members, including plakoglobin, 
p120, and p0071, can assemble into both adherens junctions and desmosomes, suggesting 
their roles in regulating the cross-talk between the two kinds of junctions.  
Besides their roles at cell-cell junctions, ARM repeat-containing proteins also undergo 
nuclear translocation to play nuclear functions.  Through their dual presence, the ARM 
repeat-containing proteins have the potential to allow changes in cell adhesion and junction 
formation to affect transmembrane signaling and nuclear gene transcription.  Among the 
family, β-catenin has been studied most thoroughly with respect to nuclear functions in the 
canonical Wnt/β-catenin signaling pathway (9, 10).  This signaling pathway is regulated 
through the controlled degradation of β-catenin in the cytoplasm.  In the absence of Wnt 
ligands, β-catenin is phosphorylated by glycogen synthase kinase 3β (GSK3β) and caseine 
kinase 1 (CK1) within a degradation complex.  Phosphorylated β-catenin is then 










Figure 2-9.  Members of the Armadillo Protein Family.  (A)  The members of 
armadillo protein family were illustrated.  ARM repeat-containing proteins can be divided 
into three subfamilies referred to by representative members: 1. β-catenin (β-catenin, 
plakoglobin); 2. p120 [p120, NPRAP (neural plakophilin-related arm-protein), ARVCF 
(Armadillo repeat gene deleted in velo cardio-facial syndrome) and p0071]; and 3. 
plakophilins (plakophilin 1-3).  The yellow boxes indicate ARM repeats.  (B)  Amino 
Acid sequence of p0071 and LBP-4.  The amino acid sequence of p0071 was listed.  The 
blue and pink boxes indicate the ARM repeats in p0071.  The start and ending amino acid of 











degradation, the amount of β-catenin is maintained at low levels in the absence of Wnt 
ligands.  Wnt ligands can bind to the cell surface receptor Frizzled and ultimately lead to 
inactivation of the degradation complex mentioned above.  Inactivation allows the 
accumulation of β-catenin in the cytoplasm, which eventually leads to nuclear translocation of 
β-catenin.  Upon entry into the nucleus, β-catenin interacts with transcription factors like 
T-cell factor (TCF) and lymphoid enhancer-binding factor (LEF) (11).  β-catenin also 
interacts with transcription and chromatin co-regulatory proteins to regulate transcription (12, 
13).  Apart from TCF/LEF, β-catenin also interacts with many NRs and leads to divergent 
downstream outcomes (14-16).   
Although the nuclear function of β-catenin is well-studied, the nuclear function of p0071 
is still vague.  When p0071 was first cloned, it was noticed that besides the presence at 
cell-cell borders, p0071 has a punctate cytoplasmic distribution pattern around the nucleus.  
A putative nuclear localization signal was also observed in p0071 (17).  In addition, p0071 is 
localized at the midbody during cytokinesis and is essential for Rho signaling during cell 
division (18).  While its function in the nucleus remains largely enigmatic, it is possible that 
p0071 has nuclear roles similar to other members in this family and this nuclear function 
might be displayed through its interaction with PXR.  
It is known that β-catenin can mediate liver growth.  The loss of β-catenin can delay the 
liver regeneration after partial hepatectomy.  Aberrant activation of β-catenin is often 
observed in hepatocellular malignancies (10).  Another important observation is that 
treatment of PCN, a potent PXR agonist, can result in increased liver mass in rats and mice 
and PXR is required for this PCN-induced hepatomegaly in mice  (19, 20).  As mentioned 
above, p0071 is localized at the midbody during cytokinesis and is essential for cell division 
(18).  It is plausible that p0071 may be involved in the regulation of liver growth through its 
85 
 
interaction with PXR.  Another interesting observation is that β-catenin can regulate the 
expression of cytochrome P450 (CYPs).  In hepatocyte-specific-β-catenin knockout mice, 
the expression of CYP1A2 and CYP2E1 is almost abolished in the liver, whereas CYP3A11, 
the expression of which is regulated by PXR, is unaffected (21).  While β-catenin is required 
for CYP1A2 and CYP2E1 expression, it is interesting to see whether p0071 regulates the 
expression of CYP3A11 and other PXR target genes.  
2.4.2 The Interaction between PXR and SUG1. 
Previous studies have shown that SUG1 interacts with mouse PXR in a 
progesterone-dependent manner (4, 22).  As one of the AAA (ATPases Associated with 
diverse cellular Activities) ATPases, SUG1 is one subunit of the 19S regulatory particle of the 
26S proteasome (23).  The 26S proteasome is a huge protease complex with two major 
structural components: the 20S core particle and the 19S regulatory particle.  Structurally, 
the 20S core is cylindrical with a hollow cavity.  The 20S core harbors protease activities 
and is the place where proteins are degraded.  Two 19S regulatory particles are located at 
each end of 20S to control the entry to the 20S core.  The 19S regulatory particles recognize 
targeted substrates, unfold them, cleave the attached ubiquitin chains, open the 20S core and 
drive the unfolded polypeptide into the cavity of 20S for degradation.   
Besides its structural role in the proteasome, accumulating evidence indicates that SUG1 
is closely associated with transcription in both proteolytic and non-proteolytic ways.  In fact, 
before its identification as a subunit of the proteasome, SUG1 was reported to be a component 
of the RNA polymerase II holoenzyme in yeast (24).  Later work in yeast further confirms 
that SUG1 is required for efficient elongation of RNA polymerase II and also contributes to 
the regulation of histone modification (25, 26).  Mammalian SUG1 is also closely related to 
transcription.  Mouse SUG1 has been shown to interact with the AF-2 domain of many NRs 
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in yeast two hybrid system (27).  In mammalian cells, overexpression of SUG1 suppresses 
both the constitutive and ligand-mediated activity of hCAR1 (28).  SUG1 also regulates the 
expression of RARα target genes.  Ferry et al. showed that both overexpression and 
knockdown of SUG-1 led to reduced expression of RARα target genes.  Using CHIP and 
Re-CHIP, they demonstrated that through the interaction with SRC-3, SUG1 was recruited to 
the promoters of RARα target genes and mediated the proteasomal degradation of SRC-3.  
While the knockdown of SUG1 inhibits the degradation of SRC-3 upon ligand treatment, 
ligand-induced degradation of RARα is not affected, suggesting substrate specificity for 
degradation.  This study further proves that SUG1 links transcription and degradation 
processes (29).   
In our yeast and mammalian two hybrid systems, SUG1 interacts with hPXR-LBD.  
Previously, it has been shown that both progesterone and endocrine-disrupting chemicals like 
phthalic acid and nonylphenol can activate PXR.  Overexpression of SUG1 inhibits 
progesterone-mediated transcription of PXR but not endocrine-disrupting chemicals-mediated 
transcription (22).  While it is clear that the effects of SUG-1 on PXR transactivation are 
differential with various PXR agonists, the underlying mechanism(s) requires further 
investigation.  Our understanding of the proteasome and its role in regulating transcription is 
increasing rapidly, but the exact role of SUG1 is still unclear.  Whether SUG1 facilitates the 
assembly of transcription complex, functions as a chaperone to selectively facilitate the 
degradation of certain proteins, or simply recruits the proteasome to the promoter of target 
genes requires further investigation.  Future studies will be required to characterize the 




2.4.3 The Interaction between PXR and SHP. 
The lack of the DNA binding domain makes SHP an atypical member of the NR family.  
Highly expressed in the liver, SHP plays an important role in regulating bile acid homeostasis 
and its expression is under the control of another liver-enriched NR- FXR (30, 31).  Bile 
acids are synthesized in hepatocytes through a multi-step process.  The first and rate limiting 
step is catalyzed by cholesterol 7-α-hydroxylase, also known as cytochrome P450 
7A1 (CYP7A1).  SHP has been shown to negatively regulate CYP7A1 gene expression 
through its interaction with LRH-1, a positive regulator of CYP7A1 expression (31, 32).  
When bile acid levels increase, they can activate FXR to induce the expression of SHP.  
Through the inhibition of CYP7A1, SHP reduces the production of bile acids, forming a 
feedback loop to maintain bile acid homeostasis.    
Besides LRH-1, SHP has been shown to interact with other NRs (30, 33-37).  The 
interaction between SHP and NRs often leads to decreased transcriptional activity of these 
NRs, because the binding between SHP and NRs alters the interaction between NRs and 
co-regulatory proteins.  Though, there are some exceptions: SHP has been shown to augment 
the transcriptional activities of PPARα and PPARγ (38, 39). 
  SHP can interact with PXR in a ligand dependent manner to suppress the transcriptional 
activity of both human and mouse PXR.  The interaction between PXR and SHP inhibits the 
binding of SRC1 to PXR and also decreases the DNA binding ability of PXR (5).  In our 
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yeast two hybrid assay, we identified SHP as an interacting protein for hPXR-LBD.  
Increasing evidence suggests that the regulation between SHP and PXR occurs at multiple 
levels.  While SHP inhibits PXR transcriptional activity, the activation of PXR also leads to 
decreased SHP expression (40).  Moreover, just like SHP, the expression of PXR is also 
regulated by FXR, indicating the intense cross talk between different NRs (41). 
  2.4.4 The Interaction between PXR and SMRT 
  SMRT is a well-known transcriptional regulatory protein that suppresses the 
transcriptional activity of many transcription factors.  The SMRT that we identified from the 
human liver cDNA library is a C-terminal fragment.  The protein encoded by the cDNA 
contains the well-identified NR-interacting domain-2 (ID-2) but not ID-1 of SMRT, which is 
in accordance with the previous finding that hPXR preferably binds to ID2 of SMRT (42).  
It is proposed that without ligands PXR is associated with co-repressors like SMRT to 
actively inhibit target gene expression.  The binding of ligand leads to a conformational 
change of PXR that dissociates corepressors and allows the recruitment of coactivators and 
basal transcriptional machinery to initiate transcription (6).  However, in our mammalian 
two hybrid assay, rifampicin treatment did not significantly decrease the interaction between 
PXR and SMRT.  At first glance, our results contradict the NR activation model.  However, 
other research groups have also observed an interaction between PXR and SMRT in the 
presence of rifampicin (43, 44).  Two major splicing isoforms have been identified for 
SMRT: α and τ, where SMRTα contains an extra 47-amino acid sequence after the ID2 motif 
(45).  These two isoforms had similar cellular distribution patterns and similar transcription 
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repression activities.  However, they interact with PXR in different patterns.  Whereas the 
interaction between SMRTτ and PXR can be dissociated by ligand treatment, the interaction 
between SMRTα and PXR is resistant to ligand.  The SMRT in our assay is the fragment of 
SMRTα, and our results that rifampicin did not significantly decrease the interaction between 
PXR and SMRT are consistent with the findings from Li and colleagues (46).  
The two different IDs in SMRT exhibit different binding affinities toward different NRs.  
Different NRs also have different preferences toward the two SMRT isoforms.  Moreover, 
the expression patterns of the two isoforms are diverse in different tissues, which might 
contribute to the tissue-selective effects of NRs (45).  Since the interaction between PXR 
and SMRTτ can be dissociated by ligand treatment, it is plausible to assume that the 
PXR-SMRTτ interaction may be more relevant in the inductive response of PXR activation 
by ligands, while the PXR-SMRTα interaction may be more related to PXR ligand induced 
repression.   
 
2.5 Conclusions 
It is clear that signaling pathways can regulate PXR function.  Some xenobiotics can 
indirectly activate PXR by modulating cellular signaling pathways.  The identification of 
novel interacting proteins for PXR is an important field which will undoubtedly improve our 
understanding of PXR activities and the signaling pathways that regulate its function. 
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The yeast two hybrid system is easy to perform, the sensitivity of the assay is high, and 
since it is performed in a higher eukaryotic system, it can overcome the deficiencies in 
bacterial cells or in in vitro systems where some post-translational modifications might be 
unavailable.  Because of the advantages mentioned above, the yeast two hybrid system has 
been widely used to detect known proteins for interactions, to define domains for interactions, 
and to screen cDNA libraries for novel interaction proteins.  Inspired by the yeast two hybrid 
system, other systems have been developed to study biomolecular interactions, such as the 
mammalian two hybrid system that detects protein-protein interactions, the one hybrid system 
that detects DNA-protein interactions (47, 48), and the three hybrid system that detects RNA 
protein interactions (49).  While the yeast two hybrid system is a good method to screen 
different cDNA libraries for novel interacting proteins, the difference between yeast and 
mammalian cells needs to be considered.  It is necessary to confirm the results from yeast in 
mammalian cells.  Nonetheless, the yeast two hybrid system is an excellent method for 
initial screening purposes.   
From our screening results, both novel and known proteins that interact with hPXR-LBD 
were identified.  As an important xenobiotic sensor which also plays important roles in many 
physiological and pathological processes, the full understanding of PXR function and related 
signaling pathways will definitely benefit the clinic.  Sixteen years after the identification of 
PXR, the regulation of PXR activity is still under active investigation.  Through the finding 
of new interacting proteins and the refinement of the currently recognized roles, the discovery 
of new, meaningful functions for PXR can be anticipated.  The new understanding of PXR 
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Chapter 3: Characterization of PXR Ubiquitination 
3.1 Introduction to Ubiquitin Proteasome System (UPS) 
In the yeast two hybrid screening described in chapter 2, SUG1 was identified as a 
PXR-interacting protein.  As one of the AAA (ATPases Associated with diverse cellular 
Activities) proteins, SUG1 is a subunit of the 19S regulatory particle of the 26S proteasome 
(1).  The mammalian 26S proteasome is a large protease complex with two major structural 
components: the 20S core particle and the 19S regulatory particle.  The 20S core harbors 
protease activities and is where proteins are degraded.  Two 19S regulatory particles are 
located at each end of the 20S to control the entry of proteins into the 20S core.  The 19S 
regulatory particle recognizes targeted substrates, unfolds them, cleaves off the attached 
ubiquitin chains, opens the 20S core and drives the unfolded polypeptides into the cavity of 
the 20S core for degradation.   
To maintain the cellular homeostasis, the 19S regulatory particles and the 20S core 
particle form the 26S proteasome to eliminate misfolded or damaged proteins, unassembled 
polypeptide chains, short-lived regulatory proteins and abnormal proteins.  However, this 
process must be strictly regulated, so that abnormal proteins can be eliminated efficiently 
while functioned proteins are not degraded unintentionally.  This regulation is achieved 
through regulated ubiquitination, which labels unwanted proteins for degradation.  In most 
cases, proteins are selected for proteasomal degradation based on the presence or absence of 
ubiquitination.  However, exceptions do occur where some proteins are degraded by the 
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proteasome without being previously ubiquitinated (2, 3).  
Ubiquitination is a type of post-translational modification that occurs when ubiquitin, a 
small regulatory protein, is covalently attached to the lysine residue(s) of target proteins.  
This process requires the function of a cascade of enzymes, including E1 (ubiquitin-activating 
enzyme), E2 (ubiquitin-conjugating enzymes) and E3 (ubiquitin ligases).  During the 
ubiquitination process, ubiquitin is initially activated by E1 in an ATP-dependent manner, 
which leads to the attachment of ubiquitin to the E1 enzyme through a thioester bond.  
Activated ubiquitin is then transferred to E2 through a trans(thio)esterification reaction.  E3 
facilitates the final step of ubiquitination where the carboxyl terminus of ubiquitin is attached 
to the ɛ-amino group of a lysine in target proteins through an isopeptide bond (4).  A normal 
cell typically contains a few E1s and dozens of E2s.  While the number of E1 and E2 
enzymes is limited, hundreds of E3s have been identified.  It is believed that substrate 
recognition is achieved through different types of E3s (5, 6).   
Mono-ubiquitination, multi-mono-ubiquitination and poly-ubiquitin chains can be 
formed through attachment to lysine residue(s) within substrates and the lysine residue(s) 
within ubiquitin.  There are seven lysines in ubiquitin, K6, K11, K27, K29, K33, K48 and 
K63, all of which can be involved in ubiquitin chain formation.  Moreover, the ubiquitin 
chain can also be formed via the N-terminal methionine of each ubiquitin (7).  The linkage 
type of the ubiquitin chain determines the fate of ubiquitinated proteins, since different 
linkages give rise to distinct three-dimensional topologies that can lead to specific recognition 
with various interacting proteins (8).  Poly-ubiquitination through K48 of each ubiquitin 
usually labels modified proteins for degradation by the 26S proteasome (9).  Poly-ubiquitin 
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chains linked through other lysines can lead to nonproteolytic outcomes, such as activation of 
protein kinases, activation of transcription factors, and the orchestration of DNA repair 
processes.  In addition to the K48-linked poly-ubiquitin chain, poly-ubiquitin chain formed 
on K63 of ubiquitin has also been intensively-studied.  K63-linked poly-ubiquitin chain 
usually mediates the recruitment of binding partners for ubiquitinated substrates and plays 
important roles in DNA repair and protein kinase activation in the NF-κB pathway (10). 
Ubiquitin and poly-ubiquitin chains attached to substrates can be disassembled by 
deubiquitination enzymes.  Therefore, ubiquitination is a dynamic and reversible process, 
which also makes it well-suited to regulate dynamic processes like transcription.  
3.2 Regulation of Gene Expression by UPS 
The UPS is closely related to transcription.  The proteasome and its subunits have been 
proposed to regulate transcription in both proteolytic and non-proteolytic ways.  
Transcription can be divided into three distinct steps: transcription initiation, elongation, and 
termination.  The proteasome and its subunits play pivotal roles in all steps and control both 
the magnitude and temporal aspects of gene expression.  
3.2.1 Proteolytic Roles of UPS in Transcription 
Transcription is a dynamic process and the binding of transcriptional factors to target 
gene promoters is essential for initiating transcription.  On the other hand, timely removal of 
transcription factors is of equal importance for efficient transcription.  Proteasomal 
degradation is required for the dynamic exchange of transcription factors, co-regulatory 
proteins, and basal transcriptional machinery to ensure that the correct proteins are present at 
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the right place and time for transcription to proceed efficiently. 
It is interesting to note that for most unstable transcription factors, their transcription 
activation domains overlap with sequences that are responsible for UPS-dependent 
degradation (degrons), revealing a convergence of these two different processes (11).  In 
both yeast and mammalian cells, transcriptional activity can be impaired when proteasomal 
degradation is inhibited, indicating its importance in regulating transcription.  In yeast cells, 
transcription activation by Gcn4, Gal4 and Ino2/4 are all inhibited by MG132 
(N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal), which is a potent and specific 
proteasome inhibitor (12).  In mammalian cells, ERα has been shown to be degraded by the 
proteasome.  Blocking proteolysis of the proteasome using MG132 attenuates 
ligand-dependent transactivation despite the fact that the protein levels of ERα are increased 
(13).  Through the study of ERα target gene pS2 in MCF-7 cells, Metivier et al. showed that 
ERα and the transcriptional machinery were recruited to the pS2 promoter in a cyclical 
manner and each cycle corresponded to a single round of transcription (14).  Without 
proteasomal degradation, the promoter is occupied and a new round of transcription cannot be 
initiated.  Similar to ERα, inhibiting proteasomal degradation also suppresses AR-, PR- and 
CAR-mediated expression of their target genes.  MG132 prevents the release of AR from the 
promoter of prostate-specific antigen (PSA) and blocks androgen-induced PSA mRNA 
accumulation (15).  Inhibition of the 26S proteasome blocks PR-dependent transcription due 
to failed recruitment of RNA polymerase II (16).  In HepG2 cells, MG132 treatment causes 
CAR to accumulate in the cytoplasm and attenuates TCPOBOP-induced CAR transcriptional 
activation on reporter constructs containing CAR-binding DNA elements derived from human 
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CYP2B6 gene (17).  Similar results are also obtained from primary cultures of human 
hepatocytes, where proteasomal inhibition represses CAR nuclear trafficking, disrupts the 
interaction between CAR and nuclear coactivators, and inhibits the expression of target genes 
following ligand treatment (18).  However, in contrast to the NRs mentioned above, 
GR-mediated gene activation is enhanced by blocking proteasomal activities (19, 20).  
Inhibiting proteolysis of the proteasome has been shown to block GR mobility, immobilize 
GR within the nuclear matrix, and increase its transcriptional output.  
The differential influences of proteasomal inhibition on the function of different NRs 
suggest a sophisticated relationship between the proteasome and the NR family.  From the 
results discussed above, it is plausible to propose that the 26S proteasome might differentially 
regulate the activities of different NRs.  However, in the examples cited above, only a few 
target genes of each NR are examined in the study.  Using a genomic approach, Kinyamu et 
al. examined the impact of proteasomal inhibition on GR- and ER-mediated gene 
transcription in MCF-7 cells.  The results indicate that inhibition of proteasome activity 
affects gene expression by GR and ER in a similar manner.  For both GR and ER, after 
proteasomal inhibition, some target genes are upregulated, whereas some are downregulated, 
suggesting these two receptors are similar in their requirement of proteolytic activity for 
target gene expression.  In addition, this also suggests that the requirement for proteolytic 
activity is gene specific, instead of NR specific (21). 
Besides promoter clearance, the 26S proteasome is also associated with transcriptional 
termination.  The 26S proteasome has been shown to be located at regions that correlate with 
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RNA polymerase II build-up, such the 3′ ends of genes, sites of UV damage and other regions 
that present transcriptional pause sites.  The activities of proteasomal degradation are 
proposed to resolve these stalled complexes.  While inhibition of the 19S decreases 
transcriptional elongation, inhibition of the 20S has been shown to decrease transcriptional 
termination (22).  Furthermore, the proteasome can regulate transcription on other levels.  
In the canonical NF-κB1 signaling pathway, NF-κB1 is first synthesized as a 105 kDa 
precursor, which needs to be processed by ubiquitination and proteasome-dependent trimming 
to become the mature p50 transcription factor (23).  After maturation, p50 is held in the 
cytoplasm by its inhibitor protein IκBα.  When stresses are presented to activate the NF-κB 
pathway, IκBα is phosphorylated, ubiquitinated, and then degraded by the 26S proteasome.  
Degradation of IκBα allows NF-κB to translocate into the nucleus and activate its target genes.  
Thus, the UPS functions not only in the regulated processing of precursors into active proteins, 
but also in the degradation of inhibitor protein of transcription factors (23).   
3.2.2 Non-Proteolytic Roles of UPS in Transcription 
SUG1 was previously recognized as a transcriptional regulator before its identification as 
a component of the 19S regulatory particle of the 26S proteasome (24).  Subsequently, a 
second yeast 19S subunit, Sug2/Rpt4, is also found to interact with the yeast transcriptional 
activator Gal4 (25).  At first, these findings were suggested to link proteolytic events with 
transcription.  However, mutations that block the proteolytic functions of the 20S subunit do 
not affect the roles of SUG1/2, suggesting that proteolysis is not required and that SUG1/2 
might have non-proteolytic functions (26).  Another piece of evidence suggesting 
101 
 
non-proteolytic functions of the proteasome is from genome-wide chromatin 
immunoprecipitation (ChIP) analysis of yeast.  The results revealed that proteasomal 
proteins bind to the majority of yeast genes.  There is widespread overlap between 19S and 
20S subunit binding sites, suggesting that these subunits might constitute the 26S proteasome 
at those sites.  However, there are some genes which are only associated with either the 19S 
or the 20S subunit, but not both, indicating these subunits may function independently of one 
another and that the intact 26S proteasome proteolytic function is not required (27, 28).  19S 
ATPases are localized both at promoters and transcribed regions, and are suggested to 
regulate transcriptional initiation and elongation (29, 30).  The 20S associates mainly with 
the 3′ ends of genes and is suggested to contribute to transcriptional termination (22).  
19S ATPase activity has also been shown to be essential for the formation of 
transcription pre-initiation complexes (PIC) (31).  Both SAGA 
(Spt-Ada-Gcn5-acetyltransferase) and TFIID (Transcription factor-IID)-dependent 
transcriptional activation have been characterized in yeast cells (32).  SAGA is a 
multi-subunit complex with histone acetyltransferase (HAT) and deubiquitinase activities.  
TFIID is composed of TBP (TATA-box binding protein) and 14 different TBP-associated 
factors (TAFs).  SAGA and TFIID interact with transcription activators to stimulate 
transcriptional initiation and activation.  Both SAGA and TFIID complexes are highly 
conserved from yeast to human, and play crucial roles in eukaryotic gene activation (32).  
Lee et al. reported that the 19S regulatory particle enhanced the interaction between Gal4 and 
SAGA.  This enhancement is dependent on 19S ATPase activity, but not the 20S core 
particle (33).  Similarly, regulatory roles of the 19S regulatory particle at TFIID-dependent 
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genes have also been observed.  The 19S regulatory particle but not the 20S core particle is 
recruited to RPS5 gene promoter to enhance the recruitment of TFIID to the promoter for 
transcriptional initiation, extending this non-proteolytic function of the proteasome in 
transcription (34).  The 19S regulatory particle has also been shown to enhance elongation 
independent of proteolysis.  Transcriptional elongation is defective upon inactivation of 
Sug1.  In contrast, inactivating proteolytic function of the 20S core particle does not affect 
elongation (30).  The same effect is also confirmed in mammalian systems, indicating that 
the nonproteolytic activity of the 19S regulatory particle maybe a common mechanism in 
transcription in eukaryotes (35). 
Besides the proteasome, ubiquitination modification also directly affects transcriptional 
activities of transcription factors, such as in the case of p53.  p53 is a key regulator of 
cell-cycle control, apoptosis, and genomic stability.  Studies indicate that ubiquitinated p53 
is bound to promoters of genes associated with growth arrest but not genes associated with 
apoptosis, suggesting that p53 ubiquitination contributes to its selection of transcriptional 
targets (36).  Another example is the yeast transcription activator, Met4, which regulates 
sulfur metabolism in yeast.  Ubiquitylation of Met4 turns off the expression of its target 
genes, without invoking its proteolysis (37). 
As a ligand activated-NR, PXR is an important regulator of xenobiotic metabolism and 
clearance.  Studies indicate that PTMs like phosphorylation also affect PXR activities, 
representing another level of regulation (38).  However, the ubiquitination of PXR has not 
been fully studied.  Previous studies demonstrate that mouse PXR interacts with SUG1, and 
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a potential E3 ligase for PXR has been identified (39-41).  In our laboratory, human PXR 
ligand binding domain was found to interact with SUG1 in a yeast two hybrid screening and 
this interaction was further confirmed in mammalian cells.  Here we identify that PXR is a 
target of UPS and that the UPS affects the transactivation capacity of PXR.  Moreover, the 
crosstalk between ubiquitination and SUMOylation of PXR is explored.  These data provide 
an additional link between nuclear receptor-mediated gene transcription and the UPS.   
 
3.3 Materials and Methods 
Plasmids and Chemicals.  Unless otherwise indicated, all chemical compounds were 
purchased from Sigma and all cell culture supplements were purchased from Gibco.  The 
full-length mouse and human PXR expression vectors were described previously (42, 43).  
To construct the FLAG-tagged mouse PXR expression vector, the cDNA encoding murine 
PXR was excised from pSG5-mPXR expression vector using EcoRI and inserted into 
pCMV-Tag 2B (Agilent).  To construct the FLAG-tagged human PXR expression vector, 
the cDNA encoding human PXR was excised from pSG5-hPXR expression vector using 
EcoRI and SalI sites and was inserted into pCMV-Tag 2B (Agilent) using EcoRI and SalI 
sites.  pRK5-HA-Ubiquitin-WT, K48R and K63R plasmids were obtained from Addgene.  
HA-ubiquitin-WT, K48R and K63R were subcloned into pcDNA4/Hismax A expression 
vector (Invitrogen) using EcoRI and NotI sites.  pcDNA4/Hismax-HA-Ubiquitin-K48, 63R 
was generated using the QuikChange Mutagenesis system (Stratagene).  
pcDNA4-Hismax-Ubiquitin-K48R was used as template and the primer used for site-directed 





Non-His-tagged SRα-HA-SUMO1 and pcDNA3-HA-SUMO3 plasmids were obtained from 
Addgene. 
Cell-based Ubiquitination Assay.  Hepa1-6 cells were transfected using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.  48 hours after 
transfection, the cells were harvested in Gua 8 buffer (6M guanidinium-HCl, 10mM Tris, 
100mM sodium phosphate buffer, pH 8.0), sonicated, the cell lysates cleared by 
centrifugation and mixed with 30μl of Talon metal affinity resins (Clontech) equilibrated in 
Gua8 buffer.  The mixture was incubated with rotation for 2 hours at room temperature and 
washed twice in Gua 8 buffer, three times in Urea 6.5 buffer [8M urea (Fisher Scientific), 
10mM Tris, and 100mM sodium phosphate buffer, pH 6.5, supplemented with 20mM 
imidazole (Fisher Scientific)] and once in 1×PBS.  After the final wash, the beads were 
resuspended in 30μl of 2×SDS-PAGE loading buffer supplemented with 50mM DTT 
(dithiothreitol), boiled for 5 min, and the proteins resolved by 10% SDS-PAGE.  The gel 
was transferred to polyvinylidene difluoride membrane and probed with anti-PXR antibody 
(sc-48340, Santa Cruz) or anti-HA antibody (MMS-101P, Covance). 
Primary Human Hepatocyte Culture, Total RNA Isolation, Reverse Transcription, 
and Real-Time Quantitative-Polymerase Chain Reaction Analysis.  The primary human 
hepatocytes were derived from samples collected and provided by the University of Kansas 
Medical Center, Department of Pharmacology, Toxicology and Therapeutics Hepatocyte Core 
Lab and the KU Liver Center.  Freshly isolated human hepatocytes were plated at a density 
of 5× 10
5
 cells/well in 12-well plates coated with 0.2 mg/ml type I collagen.  Isolated 
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hepatocytes were maintained in Dulbecco’s Modified Eagle’s Medium supplemented with 
100 nM dexamethasone, 100 nM insulin, 100U/ml penicillin G, 100μg/ml streptomycin, and 5% 
bovine calf serum and kept at 37°C in a humidified incubator with 95% air and 5% CO2.  
Hepatocytes were allowed to attach to the plate for 4 hours and then the medium were 
changed to William’s Medium E supplemented with 100 nM dexamethasone, 0.1 mg/ml 
Matrigel (BD Bioscience), 2 mM L-Glutamine, 1×ITS, 100U/ml penicillin G, and 100μg/ml 
streptomycin.  Cells were treated with vehicle (DMSO), 10 μM rifampicin, or 10 μM 
MG132 for the indicated time points.  Total RNA was isolated from hepatocytes using the 
RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions.  2µg of RNA was 
reverse transcribed using random primers (Promega).  Reverse transcription cycling 
conditions were 25°C for 10 min, 42°C for 60 min, and 95°C for 5 min.  Equal amounts of 
cDNA were used in real-time quantitative polymerase chain reactions (RT-qPCRs).  
Reactions included 1 X Power SYBR Green (Applied Biosciences) and 300nM gene-specific 








RT-qPCR was performed using the StepOnePlus Real-Time PCR System (Applied 
Biosystems).  Cycling conditions were 95°C for 10 min followed by 45 cycles of 95°C for 
10s and 60°C for 1 min.  All data were normalized to β-actin and fold induction was 
calculated using the ΔΔ
ct
 method.     
 
3.4 Results 
Ubiquitination of PXR in Hepa1-6 Cells.  Previously, our laboratory has shown that 
PXR is ubiquitinated in HeLa cells.  In the present study, Hepa1-6 cells were used to assess 
the ubiquitination level of PXR.  Hepa1-6 is a mouse hepatoma cell line that harbors liver 
specific properties (44).  Since PXR is mainly expressed in the liver and intestine, Hepa1-6 
cells are more relevant to our study compared to HeLa cells.  Utilizing the previously 
described mammalian ubiquitin expression vector in which an N-terminal HA-epitope was 
fused to ubiquitin, a novel ubiquitin expression vector containing an extended N-terminus to 
include a (His)6-tag and an X-press tag followed by an HA epitope fused in frame to ubiquitin 
was generated.  The resulting form of ubiquitin adds approximately 17 kDa to the size of 
PXR in our cell-based ubiquitination assay.  In the assay, (His)6-ubiquitin and PXR were 
co-transfected into Hepa1-6 cells.  Affinity resin was used to enrich (His)6-tagged ubiquitin 
and ubiquitinated proteins.  As shown in Fig. 3-1, when PXR and (His)6-ubiquitin were 
co-expressed in cells, a single prominent band was observed above the unmodified PXR band, 






Figure 3-1.  Detection of Ubiquitinated PXR in Hepa1-6 Cells.  Hepa1-6 cells were 
transfected with indicated plasmids to express PXR and/or His-tagged wild type ubiquitin.  
Cells were treated with MG132 for 18 hours, and then lysed in denaturing buffer.  
Ubiquitinated proteins were purified by using cobalt-linked agarose beads.  The blot was 
probed for PXR immunoreactivity using a monoclonal antibody that recognizes the human 







weight smears began to appear, suggesting the formation of ubiquitin chains.  Moreover, the 
chain formation was enhanced upon increasing MG132 concentration.  These data suggest 
that in Hepa1-6 cells, PXR is a molecular target of the ubiquitin-proteasome pathway. 
The Characterization of the Linkage Type of Ubiquitin Chains on PXR.  While 
ubiquitination of PXR has previously been demonstrated, the precise molecular nature of the 
ubiquitin linkage and its influence on the biological activity of PXR is unknown.  Expression 
vectors for (His)6-tagged wild type ubiquitin, K48R ubiquitin (lysine 48 in ubiquitin is 
mutated to arginine), K63R ubiquitin (lysine 63 in ubiquitin is mutated to arginine), and K48, 
63R ubiquitin (lysines 48 and 63 in ubiquitin are mutated to arginines) were generated.  
Hepa1-6 cells were co-transfected with expression vectors encoding ubiquitins and PXR and 
then subjected to the cell-based ubiquitination assay.  As shown in Fig. 3-2, heavily 
ubiquitinated PXR was detected when PXR and wild type ubiquitin were co-expressed in the 
cells.  When Ub-K48R was co-expressed with PXR, ubiquitin chain formation was reduced.  
However, when Ub-K63R was co-expressed with PXR, ubiquitin chain formation was 
completely intact compared to wild type ubiquitin.  When the double mutant Ub-K48, 63R 
construct was used in the assay, ubiquitin chain formation was also decreased, while the 
appearance of a single prominent band indicated that PXR was still mono-ubiquitinated.  
Taken together, these data indicate that K48 is the primary site of chain formation on 
ubiquitin that is linked to a single lysine residue in PXR protein.  It is widely recognized that 
ubiquitin chain formation through lysine 48 in ubiquitin is a canonical signal for targeting 
substrate proteins for proteasome-mediated degradation (9).  Therefore, these data indicate 





Figure 3-2. Characterization of PXR Ubiquitination.  Hepa1-6 cells were transfected with 
plasmids encoding PXR and indicated ubiquitin mutants.  48 hours after transfection, cells 
were lysed using denaturing buffer.  Ubiquitinated proteins were purified by using 
cobalt-linked agarose beads.  The blot was probed for PXR immunoreactivity (sc-48340, 








signal-dependent degradation.  These data are consistent with those obtained for other NRs, 
and fit the current paradigm that ubiquitination regulates the clearance of NRs from their 
target gene promoters. 
The Effects of UPS on PXR Transactivation.  Previously our laboratory has shown 
that treatment with proteasome inhibitors repressed rifampicin-inducible PXR transactivation 
capacity in reporter gene assays using an engineered PXR reporter gene with the xenobiotic 
response enhancer element (XREM) from the CYP3A4 promoter (45).  Moreover, 
overexpression of ubiquitin in CV-1 cells also repressed rifampicin-inducible PXR 
transactivation in XREM reporter assays.  Since the data discussed above were all generated 
from immortalized cell lines using engineered reporter gene, primary human hepatocytes 
were employed to understand how the UPS regulates endogenous hPXR target genes.  
Primary human hepatocytes were treated with rifampicin in the presence or absence of the 
proteasome inhibitor MG132 for different durations of times prior to isolation of total RNA.  
The expression levels of CYP3A4, a well-characterized human PXR target gene, were 
determined by RT-qPCR.  As shown in Fig. 3-3, 3 hours of drug treatment had no significant 
effect on CYP3A4 expression.  When cells were treated for 6 hours and 18 hours, rifampicin 
treatment significantly increased CYP3A4 expression.  Co-treatment with MG132 decreased 
the expression of CYP3A4 at these time points, suggesting the inhibition of 26S proteasome 
impaired transactivation ability of PXR.  These data provide an additional link between 
NR-mediated gene transcription and the UPS.   
The Crosstalk between Ubiquitination and SUMOylation.  Different 





Figure 3-3.  MG132 Inhibits the Expression of CYP3A4 in Primary Cultures of Human 
Hepatocytes.  Primary cultures of human hepatocyte were treated with vehicle (0.1% 
DMSO), Rif (10μM), MG132 (10μM), or Rif together with MG132 for indicated time points.  
Total RNA was isolated and RT-qPCR analysis was performed to determine the expression 
level of CYP3A4 under different treatments.  All data are normalized to β-actin levels and 
data are expressed as fold regulation compared with that observed in vehicle-treated group at 





discussed in Chapter 1.  Interaction between ubiquitination and SUMOylation at the level of 
PXR has been postulated, but the molecular mechanism and the biological consequence of 
such an interaction has not been well-described.  We next sought to determine whether 
promoting SUMOylation of PXR affects its ubiquitination status.  As shown in Fig. 3-4A, 
transfection of Hepa1-6 cells with expression vectors encoding (His)6-ubiquitin and PXR 
produced detectable forms of ubiquitinated PXR in the absence and presence of the PXR 
ligand, PCN.  Transfection with PIASy, the identified E3 that promotes SUMOylation of 
PXR, together with either non-His-tagged SUMO1 or SUMO3 produced increased levels of 
unmodified PXR.  No SUMOylation of PXR was detected here because neither SUMO1 nor 
SUMO3 was His-tagged, and they could not be pulled down by talon metal affinity resins.  
When (His)6-tagged ubiquitin was transfected together with PIASy and either SUMO1 or 
SUMO3 expression vectors, ubiquitination of PXR was dramatically increased.  These data 
indicate that PIASy-mediated SUMOylation of PXR stabilizes the protein, likely through 
prevention of ubiquitin-mediated degradation.  Examination of total protein ubiquitination 
using an anti-HA antibody detected increased ubiquitination levels in response to expression 
of PIASy together with SUMO1 or SUMO3, as shown in Fig. 3-4B. 
 
3.5 Discussion 
Ubiquitination influences the functions of target proteins by either affecting their 










Figure 3-4.  Crosstalk between Ubiquitination and SUMOylation in Hepa1-6 Cells.  
Hepa1-6 cells were transfected with indicated plasmids.  While ubiquitin is 
(His)6-HA-tagged, both SUMO1 and SUMO3 are non-His-tagged.  After transfection, cells 
were treated with PCN, a PXR ligand, for 24 hours, and then lysed using denaturing buffer.  
Ubiquitinated proteins were purified by using cobalt-linked agarose beads.  The blots were 
probed with an anti-FLAG antibody to detect PXR immunoreactivity (PA1-984B, Thermo 
Scientific) (A), and an anti-HA antibody (MMS-101P, Covance) to detect ubiquitin 













with additional signaling properties.  Because of the broad range of substrates and processes 
in which ubiquitination is involved, aberrations in the UPS have been implicated in the 
pathogenesis of many diseases.  The proteasome inhibitor bortezomib is approved by the 
FDA for the treatment of multiple myeloma and mantle cell lymphoma.  Well-known for 
their roles in protein destruction, the contribution of UPS to transcription and the following 
protein synthesis was unexpected.  However, accumulating studies support that the 
proteasome and its subunits are closely involved in transcriptional regulation, indicating that 
besides protein destruction, the 26S proteasome houses diverse roles in different processes.  
NR-mediated transcriptional regulation is complicated and subjected to multiple levels of 
control.  Besides the processes discussed above, the UPS can also affect NR-mediated 
transcription through regulating chromatin structures and the destruction of co-regulatory 
proteins.  The role of UPS in transcription is still under active investigation and many 
questions remain unknown.   
Data presented in this chapter further confirmed that PXR is a substrate for the UPS and 
that K48 is the primary site of chain formation on ubiquitin that was attached to PXR protein.  
Inhibition of 26S proteasome impairs rifampicin-induced expression of endogenous PXR 
target genes.  These data are consistent with those obtained for other NRs, and fit the current 
paradigm that ubiquitination regulates the clearance of NRs from their target gene promoters.  
We hypothesize that ligand-mediated activation of PXR signals PXR for destruction by the 
26S proteasome.  The cleared PXR-target promoter is then ready for another round of 
transcription, and the cycle begins anew.   
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Our data also indicate that the presence of SUMO increases not only the ubiquitination 
of PXR but also the global ubiquitination.  This is in accordance with a recent publication 
that indicates SUMOylation can affect function of the proteasome.  Psmd1, a subunit of the 
19S regulatory particle, is a substrate for SUMOylation.  SUMOylation of Psmd1 alters the 
composition and function of proteasome and impacts the degradation of proteasomal targets 
(46).  Overexpression of SUMO1/3 in our study might have an effect on proteasomal 
degradation and lead to accumulation of ubiquitinated proteins, including ubiquitinated PXR.  
While these findings demonstrate a possible mechanism for regulation of ubiquitin-mediated 
protein degradation by SUMOylation, more research is needed to fully understand the 
crosstalk.  Other underlying mechanisms may also exist.  For instance, the presence of 
SUMO proteins might facilitate the formation of heterologous SUMO-ubiquitin chains.  
SUMO-target ubiquitin ligases, which specifically recognize SUMOylated proteins, might be 
highly activated to catalyze ubiquitination in the presence of SUMOs.  
The degradation of a number of NRs by the UPS is connected to their phosphorylation 
status.  Phosphorylation is thought to signal substrate recognition by the enzymes in the UPS.  
A model of phosphorylation-dependent ubiquitination has been proposed (47).  PXR has 
been suggested as a phosphoprotein and its phosphorylation status can be modulated by the 
activation of PKA signaling (38, 48).  The previous findings in our laboratory indicate that 
ubiquitination of PXR can be stimulated by treatment with cAMP, suggesting crosstalk 
between phosphorylation and ubiquitination.  PXR has also been shown to be a substrate for 
acetylation (45).  Whether these PTMs of PXR compete for the same lysine residues, how 
SUMOylation, ubiquitination, and acetylation crosstalk with each other, would different 
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physiological and pathological conditions alter these PTMs, whether the regulation is 
cell-type specific, many questions remain to be answered and the data are just beginning to 
emerge.  Future studies should include an examination of the potential interaction between 
different signaling pathways and PTMs at the level of the PXR protein.   
The data presented here demonstrate that the UPS affects PXR function in regulating 
target gene expression.  The extent to which ubiquitination and/or degradation of PXR 
affects glucose homeostasis, lipid homeostasis, vitamin D metabolism, and inflammation in 
mammals requires further investigation.  The activity of PXR is affected by multiple 
signaling pathways and our previous studies indicate that the ubiquitination status of PXR is 
under the control of PKA and MEKK1 pathways.  Further studies are also required to see 
how different physiological and pathological conditions affect the ubiquitination status of 
PXR.  Considering the versatile roles of PXR in numerous physiological pathways, 
pharmacological manipulation of the complex network that contribute to the regulation of 
PXR activity may lead to the identification of therapeutic opportunities for treating of 
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Chapter 4: SUMOylation/DeSUMOylation of PXR and Their Roles in the 
Regulation of Inflammatory Response 
4.1 Introduction 
Highly expressed in the liver and intestine, PXR was discovered in 1998 based on the 
structural homology to other nuclear receptors (1).  As a ligand-dependent transcription 
factor of the nuclear receptor superfamily, PXR plays an important role in regulating 
xenobiotic metabolism and clearance.  PXR forms a heterodimer with RXRα and binds to 
PXR response elements found mostly within the promoter region of its target genes.  Unlike 
other NRs, the ligand binding domain of PXR is relatively flexible and large, which can 
accommodate the binding of numerous structurally-diverse molecules.  Thus, PXR can be 
activated by many different xenobiotics as well as endobiotics, including endocrine disrupting 
compounds, drugs and bile acids.  Once activated, PXR up-regulates the expression of genes 
encoding phase I (oxidation), phase II (conjugation) metabolizing enzymes and phase III 
transporters to increase metabolism and clearance of xenobiotics from the body, protecting 
the body from potential toxic insults (2).  However, activation of PXR is not without a risk.  
As a key regulator of drug metabolism and clearance, unexpected or abnormal activation of 
PXR may lead to adverse drug-drug and disease-drug interactions, which are major clinical 
problems increasing not only medical costs but also morbidity and mortality (3).  In addition 
to its roles in xenobiotic metabolism and clearance, PXR also has a regulatory effect on 
inflammation, glucose and lipid metabolism, bile acid and bilirubin detoxification, steroid 
hormones and vitamin metabolism.  Therefore, PXR activation has important implications in 
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many patho-physiological conditions.  Recent studies indicate that activation of PXR is 
beneficial in the treatment of diseases like cholestasis, inflammatory liver disease and 
inflammatory bowel diseases, suggesting the potential of PXR as a therapeutic target (4-6).    
Inflammation is associated with many diseases in liver and intestine.  It is of great 
importance to regulate inflammatory response.  As early as 40 years ago, before PXR was 
discovered, it was noticed that treatment with rifampicin, the prototypical human PXR ligand, 
could suppress humoral and cellular immunological response (7).  Nowadays, it is 
well-accepted that activation of PXR has a negative regulatory role on inflammatory response.  
However, the underlying mechanism is not fully understood.  Multiple studies demonstrate 
that this phenomenon is partially due to the crosstalk between PXR and NF-κB signaling.  
However, the precise molecular details involved have not been fully established and 
additional pathways which are not mutually exclusive might exist to regulate this process.   
Post-translational modifications (PTMs) are involved in the dynamic regulation of 
protein functions.  Among different PTMs, SUMOylation has gained more and more 
attention as it is closely associated with many cellular activities, including cell cycle 
progression, genome integrity, and signal transduction.  Moreover, SUMOylation also 
regulates the activities of NRs.  In a historical perspective, many components of the SUMO 
machinery were first identified as nuclear receptor-associated proteins before their 
recognition as SUMO machinery components (8, 9).  PXR, together with many other NRs, 
are substrates for SUMOylation and their activities are regulated by SUMOylation status as 
discussed in chapter 1.   
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SUMOylation involves the covalent binding of SUMO proteins to select lysine(s) within 
substrates.  There are four SUMOs in mammals, SUMO1-4.  However, SUMO4 is not 
processed for SUMOylation, and its function still remains unclear (10).  Among other 
SUMOs, SUMO2 and SUMO3 are similar to each other, whereas SUMO1 is distinct from 
them (11).  SUMO2 and 3 are well-characterized to form SUMO chains through lysine 11 
within the SUMO2/3 proteins (12, 13).  Though it is generally considered that SUMO1 lacks 
the endogenous SUMOylation site to form chains, SUMO1 chain formation has also been 
observed (14).  Just like ubiquitination, SUMOylation also requires a cascade of enzyme 
activities.  SUMO proteins are first translated as precursors and a few amino acids at the C 
terminus are cleaved off by sentrin-specific proteases (SENPs) to expose the di-glycine motif 
and form mature SUMOs.  The mature SUMOs can be activated by SUMO activating 
enzyme, E1, in an ATP-dependent manner and transferred to SUMO conjugating enzyme, E2 
(15, 16).  With the help of E3, SUMOs will be transferred to their substrates, forming the 
isopeptide bond.  SUMOylation is a dynamic and reversible process.  SENPs can remove 
SUMOs from substrates and this process is known as de-SUMOylation.  During the 
SUMOylation cycle, SENPs carry out two main functions: facilitating SUMO maturation as 
an endopeptidase and deconjugating SUMO from substrates as an isopeptidase.  Since only 
one set of E1 (SAE1/SAE2) and one E2 (UBC9) have been identified, it is believed that E3 
and SENPs specify SUMOylation substrates.  PIAS (protein inhibitor of activated STAT) 
family is one of the best characterized SUMO E3 ligase families.  PIAS proteins have RING 
finger domains, which assist in the attachment of SUMO to target substrates.  Unlike Ubc9, 
which forms a thioester bond with SUMO, PIAS proteins bind to SUMO non-covalently to 
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facilitate SUMOylation (17).  For de-SUMOylation, there are 6 SENPs identified in human 
which are involved in the deconjugating pathway, which are SENP1, 2, 3, 5, 6 and 7.  
Different SENPs have varied localizations in cells and have different specificity towards 
substrates (18).   
SUMOylation regulates a plethora of proteins in many cellular processes.  
SUMOylation of transcription factors, in most cases, is correlated with transcriptional 
repression, even though exceptions exist.  For instance, SUMOylation of T-cell factor-4 
(TCF-4) is suggested to increase its transcriptional activities (19).   SUMOylation of 
transcription factors can lead to new interaction interfaces on transcription factors that 
promote the recruitment of corepressor complexes.  Using different transcription factors, it is 
shown that histone modifying enzymes like histone deacetylases (HDACs), histone 
demethylases and histone methyltransferases can be recruited to transcription factors in a 
SUMOylation dependent manner.  Through the regulation of histone modifications, recruited 
enzymes alter the chromatin structure and actively repress gene expression (20).  In addition 
to recruiting corepressor complexes, other mechanisms have also been proposed.  For 
example, SUMOylation can compete with other post-translational modifications, regulate the 
subcellular localization of transcription factors, prevent some NRs from efficiently dimerizing 
with RXRs, and inhibit the DNA-binding of transcription factors (21). 
Besides transcription factors, many co-regulatory proteins in transcription process are 
also SUMOylated.  SUMOylation can increase the deacetylase activity and transcriptional 
repressor activity of HDAC1 and HDAC4 (22, 23).  SUMOylation of SRC-3, a coactivator 
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for transcription factors, leads to transcriptional attenuation at responsive genes (24).  These 
lead to another layer of complexity in SUMOylation-mediated transcriptional regulation.   
While SUMOylation can directly modify transcription factors, it can also regulate 
transcriptional activity through transrepression.  Many NRs have been suggested to be 
SUMOylated to repress inflammatory responses, including LXRs and PPARγ.  SUMOylated 
LXRs and PPARγ are recruited to promoters of TLR (Toll-like Receptor) target genes, where 
they prevent the removal of NCoR corepressor complexes and inhibit the expression of 
inflammatory response genes (25).  Previous work from our laboratory suggests that 
SUMOylation is also involved in human PXR mediated repression of inflammatory response 
genes (26). 
In this study, we extend our previous observation and further characterize 
SUMOylation/deSUMOylation of PXR and their potential roles in regulating PXR activity.  
We also demonstrate that activation of PXR inhibits the expression of specific LPS-inducible 
inflammatory genes in both primary hepatocytes and immortalized cell lines and further prove 
that SUMOylation is responsible for PXR-mediated repression of inflammatory response. 
 
4.2 Materials and Methods 
Plasmids and Chemicals.  The full length mouse PXR expression vector, 
CMV-mPXR, was previously described (1).  pcDNA4-HisMax-SUMO1 was subcloned 
from pcDNA3-SUMO1 utilizing BamHI site.  pcDNA4-HisMax-SUMO3 was subcloned 
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from pcDNA3-SUMO3 using BamHI and EcoRI sites.  Expression vectors for PIASs, 
SENPs and corresponding mutants were obtained from Addgene.  All chemicals were 
purchased from Sigma and all cell culture supplements were purchased from Gibco unless 
otherwise indicated.   
Primary Hepatocyte Culture.  PXR-KO mice and hPXRtg mice were generated as 
previously described (27, 28).  Primary mouse hepatocytes were isolated from male 
congenic (C57BL6) wild type, PXR knockout (KO) and humanized PXR-transgenic (hPXRtg) 
mice using a standard collagenase perfusion method.  In brief, the liver was cleared with 
wash buffer (1×HBSS, 0.5mM EGTA, 5.5mM glucose) at a flow rate of 6 ml/min for 8 min, 
and then digested for 8 min with digestion buffer [1×HBSS, 1.5 mM CaCl
2
, 5.5 mM glucose, 
~160 U/ml collagenase II (Worthington)] at a flow rate of 6 ml/min.  After digestion, the 
liver was excised and punctured open using forceps in digestion buffer to release hepatocytes.  
The cell suspension was filtered through a 100-μm nylon cell strainer (BD Falcon).  Cells 
were pelleted at 600 rpm for 5 min and washed once in plating medium (Dulbecco’s Modified 
Eagle’s Medium supplemented with 5% fetal bovine serum, 100 nM dexamethasone, 1 μM 
insulin, 2 mM L-Glutamine, 100U/ml penicillin G, and 100μg/ml streptomycin).  Dead cells 
were separated by centrifugation at 1000 rpm for 5 min in 30% Percoll (Sigma).  After one 
more wash in plating medium, cell viability was determined using trypan blue staining.  
Hepatocytes were plated in 6-well collagen-coated cell culture plates at a density of 7.0×10
5
 
living cells/well in plating medium.  After overnight attachment at 37°C in a humidified 
incubator with 95% air and 5% CO2, plating medium was replaced with William’s Medium E 
supplemented with 0.1 mg/ml Matrigel (BD Bioscience), 100 nM dexamethasone, 0.1 mg/ml 
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Matrigel (BD Bioscience), 2 mM L-Glutamine, 1×ITS, 100U/ml penicillin G, and 100μg/ml 
streptomycin.  
The primary human hepatocytes were derived from samples collected and provided by 
the University of Kansas Medical Center, Department of Pharmacology, Toxicology and 
Therapeutics Hepatocyte Core Lab and the KU Liver Center which is sponsored by the 
Department of Pharmacology, Toxicology and Therapeutics Biospecimen Core Lab and the 
Liver Center at KUMC.  Freshly isolated human hepatocytes were plated at a cell density of 
5× 10
5
 cells/well in 12-well plates previously coated with 0.2 mg/ml type I collagen.  
Isolated hepatocytes were maintained in Dulbecco’s Modified Eagle’s Medium supplemented 
with 100 nM dexamethasone, 100 nM insulin, 100U/ml penicillin G, 100μg/ml streptomycin, 
and 5% bovine calf serum and kept at 37°C in a humidified incubator with 95% air and 5% 
CO2.  Hepatocytes were allowed to attach to the plate for 4 hours and then the medium were 
changed to William’s Medium E supplemented with 100 nM dexamethasone, 0.1 mg/ml 
Matrigel (BD Bioscience), 2 mM L-Glutamine, 1×ITS, 100U/ml penicillin G, and 100μg/ml 
streptomycin.   
Total RNA Isolation, Reverse Transcription, and Real-Time 
Quantitative-Polymerase Chain Reaction Analysis.  Total RNA was isolated from cells 
using the commercially available RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
instructions.  2µg of RNA was reverse transcribed using random primers (Promega).  
Reverse transcription cycling conditions were 25°C for 10 min, 42°C for 60 min, and 95°C 
for 5 min.  Equal amounts of cDNA were used in real-time quantitative polymerase chain 
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reactions (RT-qPCRs).  Reactions included 1 X Power SYBR Green (Applied Biosciences) 
and 300nM primers specific for each gene. The sequences of each primer are as follows:  
Genes Primers 
β-actin Mouse: 
3’ primer: 5’-TAACAGTCCGCCTAGAAGCA-3’  
5’ primer: 5’-CAAGATCATTGCTCCTCCTG-3’ 
Human:  
3’ primer: 5’  CAAGATCATTGCTCCTCCTG 3’ 
5’ primer: 5’  TCATAGTCCGCCTAGAAGCA 3’  
IL-6 Mouse: 
3’ primer: 5’-CTGCAAGAGACTTCCATCCAG-3’ 
5’ primer: 5’-AGTGGTATAGACAGGTCTGTTGG-3’ 
Human:  
3’ primer: 5’-ACTCACCTCTTCAGAACGAATTG-3’  




 3’ primer: 5’-GAAATGCCACCTTTTGACAGTG-3’ 
5’ primer: 5’-CTGGATGCTCTCATCAGGACA-3’ 
Human:  
3’ primer: 5’-ATGATGGCTTATTACAGTGGCAA-3’  





3’ primer: 5’-CATTGAGCCTCATGCTCTGTT-3’  
5’ primer: 5’-CGCTGTCTGAGCGGATGAA-3’  
Cox-2 3’ primer: 5’-TTCCAATCCATGTCAAAACCGT-3’ 
5’ primer: 5’-AGTCCGGGTACAGTCACACTT-3’ 
Cyp3a11 
 
3’ primer: 5’-CCACGTTCACTCCAAATGAT-3’  
5’ primer: 5’-CAAGGAGATGTTCCCTGTCA-3’ 
CYP3A4 3’ primer: 5’-CAGGAGGAAATTGATGCAGTTTT-3’   
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5’primer: 5’-GTCAAGATACTCCATCTGTAGCACAGT-3’  
RT-qPCR was performed using the StepOnePlus Real-Time PCR System (Applied 
Biosystems).  Cycling conditions were 95°C for 10 min followed by 45 cycles of 95°C for 
10s and 60°C for 1 min.  All data were normalized to β-actin and fold induction was 
calculated using the ΔΔ
ct
 method.     
NF-κB Gene Array.  Total RNA was isolated from wild type mouse hepatocytes using 
the RNeasy Mini Kit (Qiagen) and reverse transcribed.  The commercially available Mouse 
NF-κB Gene Array (SA Biosciences, 330231 PAMM-225A) was purchased and an equal 
amount of cDNA was applied to each well before RT-qPCR was performed as described 
above.      
Analysis of IL-1Ra.  A 200 μl aliquot of cell media was removed and combined with 
200 μl 2×SDS-PAGE loading buffer supplemented with 50mM DTT.  Following removal of 
culture media, cells were harvested by scraping into 1×PBS, pelleted by centrifugation, and 
then lysed in SDS-PAGE loading buffer supplemented with DTT.  Equal amounts were 
resolved using 12.5% SDS-PAGE.  Western blot analysis was performed using a 
monoclonal antibody that recognizes human and mouse IL-1Ra (NBP1-96673, Novus 
Biologicals).  Western blot images were quantified by densitometric scanning of X-ray films 
with the UVP Biodoc-It 220 image analysis system and 1D Gel Analysis Software.  
Cell-based SUMOylation Assay.  Hepa1-6 cells were transfected using Lipofectamine 
2000 according to the manufacturer's instructions.  48 hours after transfection, cells were 
harvested in lysis buffer (6M guanidinium-HCl, 10mM Tris, 100mM sodium phosphate 
buffer, pH 8.0), sonicated, the cell lysates cleared by centrifugation and then mixed with 30μl 
of Talon metal affinity resins (Clontech) equilibrated in lysis buffer.  The mixture was 
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incubated with rotation for 2 hours at room temperature and washed twice in lysis buffer, 
three times in Urea 6.5 buffer [8M urea (Fisher Scientific), 10mM Tris, and 100mM sodium 
phosphate buffer, pH 6.5, supplemented with 20mM imidazole (Fisher Scientific)] and once 
in 1×PBS.  After final wash, the affinity resins were resuspended in 30μl of 2×SDS-PAGE 
gel loading buffer supplemented with 50mM DTT, boiled for 5 min, and the proteins resolved 
using 10% SDS-PAGE.  The gel was transferred to polyvinylidene difluoride membrane and 
probed with anti-FLAG antibody (PA1-984B, Thermo Scientific). 
Statistical Analyses.  Where appropriate, statistical differences among experimental 
groups were determined using a one-way analysis of variance followed by the Duncan’s 
multiple range post hoc test.  Letters different from each other indicate a significant 
difference between treatment groups.  Statistical differences between experimental groups 
were determined using the student’s t-test. 
 
4.3 Results 
4.3.1 The Role of PXR in Modulating the Inflammatory Response in Primary 
Cultures of Hepatocytes 
LPS-Inducible Concentration- and Time-responses Analysis of Key Inflammatory 
Mediators in Mouse and Human Primary Cultures of Hepatocytes.  To determine the 
extent to which activation of PXR alters LPS (lipopolysaccharide)-inducible gene expression, 
concentration- and time-responses of LPS-inducible IL-1β (interleukin-1β) gene expression 
were examined in mouse and human hepatocytes.  Treatment of hepatocytes with increasing 
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amounts of LPS (0.01, 0.1, 1, 10, and 100 μg/ml) for 12 hours produced robust induction of 
IL-1β expression at all concentrations examined (Fig. 4-1A).  Based on these results, 10 
μg/ml was chosen to initiate the inflammatory response in subsequent studies.  While all of 
the time points examined (1, 6, 12, 24, and 48 hours) exhibited significant increases in IL-1β 
expression level, 6 and 12 hour time points showed the largest increases (Fig. 4-1B).  
Examination of kinetics of LPS-inducible mouse and human IL-6 (interleukin-6) produced 
very similar results (data not shown).  Based on these data, 12 hours treatment was chosen to 
induce the expression of key inflammatory mediators in both mouse and human hepatocytes.  
A time-response analysis of CYP3A gene expression using PCN (10μM) as a prototypical 
mouse PXR activator and rifampicin (10μM) as a prototypical human PXR activator indicated 
that 24 hours treatment produced maximal CYP3A gene expression (Fig. 4-2).  Taken 
together, pre-treatment with PXR activators for 24 hours and subsequent co-treatment with 
LPS for 12 hours was selected for subsequent experiments to assess the effect of PXR 
activation on LPS-inducible gene expression. 
Pre-Activation of PXR Suppresses LPS-inducible NF-κB Target Genes.  An 
important transcriptional mediator of LPS signaling is the transcription factor NF-κB.  To 
determine the effect of PXR activation on the inflammatory response in primary mouse 
hepatocytes, a commercially available NF-κB PCR array was employed.  This array allows 
us to simultaneously examine the expression of 84 key genes which are responsive to NF-κB 
signal transduction.  Based on previous dose and time experiments, hepatocytes were 

















Figure 4-1.  Concentration- and Time-dependent Analysis of the Expression of 
Inflammatory Response Genes in Hepatocytes.  (A) Primary cultures of wild type mouse 
hepatocytes or human hepatocytes were treated with vehicle or indicated concentrations of 
LPS for 12 hours.  Total RNA was isolated and RT-qPCR analyses were performed to 
determine the expression of IL-1β under different concentrations of LPS treatment.  (B) 
Primary cultures of wild type mouse hepatocytes or human hepatocytes were treated with 
vehicle or LPS (10 μg/ml) for indicated time points.  Total RNA was isolated and RT-qPCR 
analyses were performed to detect the expression levels of IL-1β mRNA through time.  














Figure 4-2.  Time-dependent Induction of CYP3A Gene Expression in Primary 
Hepatocytes Derived from Mice and a Human Donor.  Hepatocytes were treated with 
vehicle (0.1% DMSO), Rif (10 μM) or PCN (10 μM) for the indicated time points.  Total 
RNA was isolated and the relative expression level of Cyp3a11 (mouse) and CYP3A4 
(human) were determined.  All data are normalized to β-actin levels and are presented as 
fold regulation.  Asterisks indicate a statistical difference from vehicle treated samples (n=3, 





experimental groups and were treated for an additional 12 hours with either vehicle, PCN 
alone, 10μg/ml LPS alone, or PCN and LPS together.  After the treatment, total RNA was 
isolated and reverse transcribed.  cDNA was subjected to the PCR array.  As shown in 
Table 4-1, treatment of primary mouse hepatocytes with LPS for 12 hours induced the 
expression of sixteen well-known NF-κB target genes.  Treatment with PCN alone repressed 
the basal expression of numerous NF-κB target genes (Table 4-2).  When compared with 
LPS treatment alone, treatment with PCN for 24 hours and subsequent co-treatment with LPS 
produced significantly lower expression levels of several notable LPS-inducible NF-κB target 
genes, including IL-1β, IL-6, Ptgs2 (also known as Cox-2, cyclooxygenase 2), and IL-1Ra 
(As shown in Table 4-3).  These data suggest that PXR represses the inflammatory response 
in a gene-specific manner, since not all NF-κB target genes were repressed by PXR 
activation.   
For the following experiments, four NF-κB target genes, Cox-2, IL-1β, IL-6, and IL-1Ra 
were chosen for in-depth study.  To further determine the role of PXR in the repression of 
the inflammatory response, hepatocytes derived from wild type or PXR-KO mice were used 
with independently designed RT-qPCR primer sets.  The integrity of PXR-KO hepatocytes 
was confirmed by analysis of the expression levels of Cyp3a11, an mPXR target gene.  As 
shown in Fig.4-3A, while PCN treatment significantly induced the expression of Cyp3a11 in 
WT hepatocytes, there was no induction in PXR-KO hepatocytes.  In accord with our 
previous publication, co-treatment with LPS diminished the induction of Cyp3a11 by PCN in 




Gene Induced by LPS Fold Induction  S.D  
Cxcl3  393.9  80.8  
IL-1β  314.4  77.4  
IL-6  128.9  43.2  
Csf3  63.4  20.4  
IL12β  52.5  12.4  
Ccl5  50.5  11.5  
Ptgs2  50.5  10.6  
Ltb  50.0  10.6  
IL-1Ra  49.7  9.2  
IL-1α  31.0  7.8  
Cxcl1  10.2  2.3  
TNFα  10.0  4.6  
Sele  6.3  2.9  
Cd74  6.3  2.1  
Vcam1  5.0  1.1  
Bcl2a1a  3.9  1.3  
Table 4-1. Treatment of Primary Cultures of Mouse Hepatocytes with LPS Increases 
Expression of NF-κB Target Genes.  Primary hepatocytes isolated from wild type mice 
were treated for 12 hours with either vehicle (0.09% saline) or LPS (10μg/ml) (n=4).  Total 
RNA was isolated and RT-qPCR using a focused panel of 84 well-known NF-κB target genes 
was performed following manufacturer’s instructions (SA Biosciences).  Data are expressed 




Genes Suppressed by PCN  Fold Suppression  S.D.  
Selp  5.1  2.4  
C3  4.2  2.0  
Csf2  4.1  0.3  
Tnfsf10  4.1  2.0  
Agt  4.1  1.9  
Myd88  3.3  1.4  
Aldh3a2  3.3  1.6  
Csf2rb  3.2  1.5  
F8  3.2  1.5  
Ifnb1  2.6  1.0  
Cfb  2.6  1.0  
Il1rn  2.5  0.8  
Ifnɣ  2.2  0.8  
Trp53  2.1  0.8  
Akt1  2.1  0.8  
Ccl22  2.1  0.8  
Nqo1  2.1  0.8  
Cxcl3  2.1  0.6  
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Mitf  2.0  0.8  
Fas  2.0  0.8  
Stat3  2.0  0.8  
Tnfrsf1b  2.0  0.8  
Rel  2.0  0.8  
Stat5b  2.0  0.8  
Xiap  2.0  0.8  
Irf1  2.0  0.8  
Fasl  2.0  0.7  
Table 4-2.  Treatment of Primary Cultures of Mouse Hepatocytes with PCN 
Suppresses Basal Expression of NF-κB Target Genes.  Cultures of mouse hepatocytes 
isolated from wild type mice were treated with either vehicle (0.1% DMSO) or 10 µM PCN 
for 24 hours (n=3).  Total RNA was isolated and reverse transcribed.  RT-qPCR using a 
focused panel of 84 well-known NF-κB target genes was performed following manufacturer’s 
instructions (SA Biosciences).  Data are reported as fold suppression + the standard 







Genes Suppressed in [LPS + 
PCN] -vs- LPS Alone  
Fold Suppression  S.D.  
Ptgs2  2.5  0.6  
Mmp9  2.5  0.8  
Cd83  2.5  0.8  
Cd74  2.5  0.6  
Il6  2.0  0.4  
Il1rn  2.0  0.5  
Il1β  1.6  0.2  
Tnfα  1.6  0.1  
Table 4-3.  Treatment of Primary Cultures of Mouse Hepatocytes with PCN 
Suppresses LPS-induced Expression of NF-κB Target Genes.  Cultures of mouse 
hepatocytes isolated from wild type mice were pre-treated with vehicle or 10 µM PCN for 24 
hours then co-treated with LPS for another 12 hours (n=3).  Total RNA was isolated and 
reverse transcribed.  RT-qPCR using a focused panel of 84 well-known NF-κB target genes 
was performed following manufacturer’s instructions (SA Biosciences).  Data are reported 
as the average fold suppression + the standard deviation (S.D.) in the co-treated (PCN+ LPS) 

















Figure 4-3.  PXR Activation Represses the Expression of LPS-inducible Inflammatory 
Response Genes.   Primary hepatocytes were isolated from wild type (C57BL/6) or 
PXR-KO mice.  After overnight attachment, cells were treated with vehicle (0.1% DMSO) 
or 10 μM PCN for 24 hours followed by an additional 12 hours treatment with or without LPS 
(10 μg/ml).  Total RNA was isolated, and the relative expression levels of (A) Cyp3a11 and 
(B) Cox-2, IL-1β, IL-6 and IL-1rn were determined by RT-qPCR.  The expression level in 
vehicle treated hepatocytes was set as 1 in each genotype.  All data are normalized to β-actin 




the expression of selected inflammatory response genes, whereas this induction was 
suppressed by the pre-activation of PXR with PCN, as shown in Fig. 4-3B,  However, in 
PXR-KO hepatocytes, no suppression was observed in the co-treatment group compared to 
LPS treatment alone, suggesting the repression is PXR-dependent.  It was noticeable that in 
PXR-KO hepatocytes the fold induction by LPS is much lower compared to WT hepatocytes.  
This can be partially explained by the fact that in PXR-KO hepatocytes, expression levels of 
inflammatory response genes are higher in the basal level, indicating a repressive role for 
PXR in regulating basal expression levels of key inflammatory mediators.  When comparing 
all the groups to vehicle-treated wild type hepatocytes, LPS-inducible IL-1β expression level 
was even higher in PXR-KO hepatocytes than wild type hepatocytes (data not shown).  
However, this only occurred in IL-1β expression level.  For other tested inflammatory genes, 
the LPS-inducible expression levels were still lower compared to wild type hepatocytes.  
These data reveal that the absence of PXR produces a condition in which the expression of 
IL-1β is heightened, and suggests that PXR contributes to the effective suppression of IL-1β 
inflammatory response through time.  Moreover, in WT hepatocytes, PCN alone could 
induce the basal expression of Cox-2, IL-1β, and IL-6, but this induction was abolished in 
PXR-KO hepatocytes.  While mechanisms underlying these phenomena are unknown, these 
data suggest that PXR plays a role in the regulation of inflammatory responses. 
The Effects of PXR Activation on IL1-Ra Expression.  Of all the NF-κB target genes 
we examined, IL-1Ra (protein product of IL-1rn gene) is of particular interest.  Unlike other 
examined NF-κB target genes which are pro-inflammatory mediators, IL-1Ra is 
anti-inflammatory.  IL-1Ra is expressed at high levels in hepatocytes.  Its expression can be 
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induced by inflammatory mediators to encode a secreted antagonist of IL-1 signaling (30, 31).  
lL-1Ra regulates IL-1α and IL-1β activity by competing with them for binding of the IL-1 
receptor.  IL-1Ra can bind to IL-1 receptor with similar affinity as IL-1α and β, but it does 
not initiate the downstream inflammatory signaling.  Through the competition with IL-1α 
and IL-1β, IL-1Ra antagonizes IL-1 inflammatory signaling.   
To further study the effect of PXR activation on IL-1Ra expression, the concentration- 
and time-dependent LPS-inducible expression of IL-1Ra were closely examined in both wild 
type mouse hepatocytes and human hepatocytes.  Treatment with LPS for 12 hours produced 
a significant increase in the expression level of IL-1Ra in a concentration-dependent manner 
(Fig. 4-4A).  For the time-dependent LPS-inducible expression of IL-1Ra, the expression 
levels were significantly induced at 6, 12, 24, and 48 hours (Fig. 4-4B).  When compared 
with the time- and concentration-response analysis of IL-1β and IL-6, the induction of IL-1Ra 
was delayed by several hours, but remained relatively high throughout the 48 hours.  These 
data indicate that the kinetics of LPS-inducible IL-1Ra gene expression is distinct from that 
observed for pro-inflammatory mediators like IL-1β and IL-6, with expression levels of 
IL-1Ra increasing at later time points and exhibiting a longer period of sustained expression.  
There are two major isoforms of IL-1Ra protein, one is a heavily glycosylated and 
secreted isoform (sIL-1Ra) and the other is an intracellular isoform (icIL-1Ra).  The 
expression and secretion of sIL-1Ra is highly inducible, whereas the expression of icIL-1Ra 
is not.  To fully examine PXR’s role in IL-1Ra expression, we examined the PXR- and 






















Figure 4-4.  LPS-induced IL-1Ra Expression in Primary Hepatocytes.  (A) Primary 
cultures of wild type mouse hepatocytes and human hepatocytes were treated with vehicle or 
indicated concentrations of LPS for 12 hours.  Total RNA was isolated and RT-qPCR 
analyses were performed to determine the expression of IL-1Ra.  (B) Primary cultures of 
wild type mouse hepatocytes and human hepatocytes were treated with vehicle or LPS (10 
μg/ml) for indicated time points.  Total RNA was isolated and RT-qPCR analyses were 
performed to detect the expression levels of IL-1Ra through time.  All data are normalized to 
β-actin levels and data are expressed as fold regulation compared with that observed in 











respectively (Fig. 4-5A).  When treated with PCN or rifampicin for 36 hours, the expression 
level of sIL-1Ra in the media increased from hepatocytes of both wild type and hPXRtg mice.  
For cells that were treated with LPS alone and cells which were pre-treated with PCN or 
rifampicin, then co-treated with LPS, the level of sIL-1Ra also increased, but the induction 
level was lower compared to PXR activation alone.  When hepatocytes from PXR-KO mice 
were used in identical experiments, PCN had no effect on sIL-1Ra protein induction.  In 
contrast, 12 hours of LPS treatment led to an enhanced induction of sIL-1Ra in PXR-KO 
hepatocytes compared to PXR-positive cultures.  Additionally, co-treatment of PXR-KO 
hepatocytes with PCN and LPS failed to diminish sIL-1Ra levels.  Taken together, the data 
presented indicate that PXR activation has both an early negative regulatory role in the 
LPS-inducible expression of key inflammatory mediators like IL-1β and IL-6, as well as a 
likely positive role in regulating ligand-inducible expression of the secreted form of IL-1Ra 
protein at later time points.  To more closely examine the potential positive role of PXR 
activation in regulating sIL-1Ra protein levels across species, a longer time-course study 
using primary human hepatocytes was conducted (Fig. 4-5B).  Treatment of human 
hepatocytes with rifampicin for 48 hours produced a robust induction in sIL-1Ra levels, 
whereas 24 hours of treatment with LPS produced less induction compared to rifampicin 
treatment.  Treatment of human hepatocytes with rifampicin for 48 hours, followed by 
co-treatment with rifampicin and LPS for an additional 24 hours produced an induction of 
sIL-1Ra much higher than rifampicin treatment alone.  These data indicate that long-term 




















Figure 4-5.  Analysis of the Secreted Form of IL-1Ra Protein in Culture Media from 
Primary Hepatocytes Isolated from Wild Type, hPXRtg, PXR-KO Mice and Human 
Hepatocytes.  (A) Primary mouse hepatocytes were isolated from the indicated genotype 
and were treated with vehicle (0.1% DMSO) or 10μM PCN for 24 hours.  Cell cultures were 
then divided into four experimental groups and were treated for an additional 12 hours with 
either vehicle, PCN alone, 10μg/ml LPS alone, or PCN and LPS together.  Western Blot 
analysis of the secreted form (sIL-Ra) and intracellular form (icIL-1Ra) of IL-1Ra was 
performed.  (B) Primary human hepatocytes were treated with vehicle (0.1% DMSO) or 
10μM Rif for 48 hours.  The cultures were then divided into four experimental groups and 
were treated for an additional 24 hours with either vehicle, Rif alone, 10μg/ml LPS alone, or 
Rif and LPS together.  Western Blot analysis of the secreted form (sIL-Ra) and intracellular 
form (icIL-1Ra) of IL-1Ra was performed.  Western Blot images were quantitated by 
densitometric scanning of the X-ray film with the UVP Biodoc-It 220 image analysis system 
and 1D Gel Analysis Software.  The numbers represent densitometric image intensity of 








4.3.2 SUMOylation Regulates the Inhibitory Role of PXR on Inflammation 
The SUMOylation and De-SUMOylation of PXR in Cell-based SUMOylation Assay.  
Hepa1-6 cell, a mouse hepatoma cell line, was used in our study.  This cell line expresses 
endogenous SUMOs at high levels, and is highly permissive for SUMOylation compared to 
other commonly used cell lines like HeLa and CV-1 cells (data not shown).  Moreover, 
Hepa1-6 cells do not express endogenous PXR (data not shown).  PIAS proteins are a family 
of well-characterized SUMO E3 ligases.  There are five unique PIAS proteins (PIAS1, 
PIASxα, PIAS3, PIASxβ, and PIASy).  Each PIAS family member exhibits distinct but 
sometimes overlapping SUMO E3 ligase enzymatic activity towards substrates.  The 
specific SUMO E3 ligase that promotes SUMO-modification of PXR is currently unknown.  
To determine which PIAS family member(s) could function as E3 ligase(s) towards PXR, 
Hepa1-6 cells were co-transfected with expression vectors encoding FLAG-tagged PXR 
together with His-tagged SUMO1 or SUMO3 and an additional expression vector encoding a 
specific member of the PIAS family.  As shown in Fig.4-6A, in the presence of PIASy, the 
SUMO(1)ylation of PXR was robustly promoted at two sites.  When SUMO3 was used in 
the same assay, more robust SUMO-chain formation was observed with PIASy.  PIAS1 and 
PIAS3 also promoted SUMO(3)ylation of PXR.  In general, the signal for SUMO(3)ylation 
was stronger than SUMO(1)ylation, indicating PXR was preferentially SUMOylated by 
SUMO3 in Hepa1-6 cells.  This is consistent with our previous publication on human PXR 
(26).  Since PIASy enhanced PXR SUMOylation, for the following study, it was used to 
promote PXR SUMOylation.   
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There is increasing recognition that regulation of SUMO modification also occurs at the 
level of de-SUMOylation.  Similar to E3 ligases, the specific SENP(s) that remove SUMO 
modification from PXR are currently unknown.  After the identification of E3 ligase for 
PXR SUMOylation, we next sought to identify the SENP family member(s) that 
de-SUMOylates PXR using a variation of our cell-based SUMOylation assay.  Expression 
vectors encoding His-tagged SUMOs, PIASy and FLAG-tagged PXR were co-transfected 
into Hepa1-6 cells together with selected SENPs as indicated in the figure.  Where available, 
the catalytically-deficient mutant form of each SENP was used as negative controls.  As 
shown in Fig. 4-6 (B), SENP2 completely abolished SUMOylation of PXR, whereas the 
catalytically deficient form of SENP2 was ineffective.  While expression of SENP1 and 
SENP6 promoted de-SUMOylation of PXR to some extent, the removal was incomplete.  It 
is noteworthy that the 52 kDa immunoreactive band that corresponds to non-modified PXR 
increases in direct proportion to the level of SUMO-modification.  These data suggest that 
PIASy-mediated SUMOylation of PXR may inhibit its proteasome-mediated degradation.  
Identical experiments using SUMO3 indicate that SENP1, SENP3, and SENP6 
de-SUMOylating enzymes selectively remove SUMO-chains, while SENP2 is the most 
effective at removing all SUMO moieties from PXR. 
Activation of PXR Suppresses the Expression of Inflammatory Response Genes in 
Hepa1-6 Cells.  It has been shown that activation of PXR repressed the inflammatory 
response in hepatocytes.  However, it was difficult to manipulate primary hepatocytes, thus 
Hepa1-6 cells were used to further the study.  mPXR expression vector was transfected into 




















Figure 4-6.  Characterization of PXR SUMOylation and De-SUMOylation.  (A) In 
order to facilitate SUMOylation of PXR, mammalian expression vectors encoding 
(His)6-tagged SUMO1/3, PIASs and FLAG-tagged mPXR were co-transfected into Hepa1-6 
cells as indicated.  48 hours post-transfection, cells were harvested in denaturing buffer and 
SUMOylated proteins were purified with cobalt-linked agarose beads.  Captured proteins 
were subjected to SDS–PAGE and subsequent western blot analysis using an anti-FLAG 
antibody (PA1-984B, Thermo Scientific).  (B) To determine the ability of SENPs to 
de-SUMOylate mPXR, expression vectors encoding (His)6-tagged SUMO1/3, PIASy, 
FLAG-tagged mPXR and various SENPs and corresponding mutants were transfected into 
Hepa1-6 cells as indicated.  48 hours post-transfection, cells were harvested in denaturing 
buffer and SUMOylated proteins were purified with cobalt-linked agarose beads.  Captured 
proteins were subjected to SDS–PAGE and subsequent western blot analysis using an 








Fig.4-7(A), introduction of exogenous PXR restored drug-inducible Cyp3a11 gene expression, 
indicating that exogenous PXR could be activated in Hepa1-6 cells.  In accordance with the 
results in WT hepatocytes, LPS also dampened PCN-induced Cyp3a11 expression in Hepa1-6 
cells.  After the confirmation that exogenous PXR functioned well in Hepa1-6 cells, we next 
sought to further examine the effect of PXR on LPS-induced inflammation.  In 
non-transfected cells, LPS treatment significantly induced the expression of both Cox-2 and 
IL-6 and PCN treatment had no repressive effect on LPS-induced gene expression, as shown 
in Fig. 4-7(B).  After PXR was introduced into the Hepa1-6 cells, PCN treatment profoundly 
repressed Cox-2 and IL-6 gene expression.  Moreover, LPS-inducible Cox-2 and IL-6 
expression was abolished in the presence of PXR, regardless of treatment with LPS or a 
combination LPS and PCN (As shown in Fig. 4-7B).  These results indicate that in Hepa1-6 
cells, exogenous PXR is a strong repressor of the inflammatory response. 
Expression of De-SUMOylation Enzymes Impairs the Ability of PXR to Suppress 
the Expression of Inflammatory Response Genes.  Previously, we demonstrated that 
SENP2 was the major enzyme that de-SUMOylates PXR and SENP6 could remove SUMO 
chains from PXR.  To further confirm the effect of SUMOylation on PXR-mediated 
repression of inflammatory mediators, expression vectors for PXR and SENP2 or SENP6 
were co-transfected into Hepa1-6 cells.  As shown in Fig. 4-8, the expression of exogenous 
PXR alone still abolished LPS-induced expression of Cox-2 and IL-6.  However, in the 
presence of SENP2 PXR no longer suppressed LPS-induced expression of Cox-2 and IL-6, 










Figure 4-7.  Activation of Exogenous PXR Represses LPS-inducible Inflammatory 
Response Genes in Hepa1-6 Cells.  Hepa1-6 cells were transfected with expression vector 
encoding FLAG-tagged mPXR.  24 hours post-transfection, cells were treated with 10 μM 
PCN for 36 hours followed by an additional 12 hours treatment with or without LPS (10 
μg/ml).  Total RNA was isolated, and the relative mRNA expression levels of (A) Cyp3a11 
and (B) Cox-2 and IL-6 were determined by RT-qPCR.  The expression level of each gene 
in vehicle treated non-transfected cells was set as 1.  All data are normalized to β-actin levels 
















Figure 4-8. The Effects of SENPs on the Expression of PXR-suppressed Inflammatory 
Response Genes.  Hepa1-6 cells were transfected with expression vectors encoding mPXR 
and SENP2 or SENP6.  24 hours post-transfection, cells were treated with 10 μM PCN for 
36 hours followed by an additional 12 hours treatment with or without LPS (10 μg/ml).  
Total RNA was isolated, and the relative mRNA expression levels of IL6 and Cox-2 were 
determined by RT-qPCR.  The expression level of each gene in vehicle treated 
non-transfected cells was set as 1.  All data are normalized to β-actin levels and are 
expressed as fold regulation. 
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while the expression of SENP6 partially restored LPS-induced IL-6 expression, it had no 
effect on LPS-induced Cox-2 expression in cells expressing exogenous PXR (Fig. 4-8).  
These data raise the question of whether SUMO chains are specifically required for the 
repression of certain genes and whether the mechanism(s) underlying PXR-mediated 
repression differs between various genes.  
 
4.4 Discussion 
Many NR ligands, like glucocorticoids are widely used as anti-inflammatory drugs.  
Numerous NRs have been shown to regulate both innate and adaptive immune systems 
through different mechanisms.  For instance, GR interferes with the assembly of co-activator 
complexes and the transcription elongation factor b complex, which are required for NF-κB 
activation, thus inhibiting the expression of NF-κB target genes (32-34).  Moreover, GR can 
modulate MAPK (Mitogen-activated Protein Kinase) signaling to inhibit the expression of 
AP-1 induced inflammatory genes (35-37).  SUMOylated LXRs, LRH1 and PPARγ can 
prevent the removal of corepressor complexes from the promoter of inflammatory response 
genes (25, 38, 39).  It is well-accepted that activation of PXR suppresses inflammatory 
response.  However, activation of NF-κB also represses PXR target gene expression.  This 
mutual repression is known as transrepression (29).  Several possible mechanisms have been 
proposed for the inflammation-induced suppression of drug metabolism and clearance.  
Inflammatory stimuli have been shown to reduce the mRNA levels of PXR and disrupt the 
association between PXR and DNA (40, 41).  Though the plausible mechanism for 
inflammation-mediated PXR target gene repression has been proposed, the underlying 
mechanism(s) for PXR-mediated repression on inflammatory response still remains vague.  
Our data indicate that SUMOylation of PXR is involved in PXR-mediated repression.  
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Over-expression of SENP2, the major enzyme that de-SUMOylates PXR, abolishes the ability 
of PXR to repress LPS-induced expression of Cox-2 and IL-6.  However, expression of 
SENP6, which removes SUMO3 chains from PXR, has a different effect on PXR-repressed 
Cox-2 and IL-6 expression.  It is plausible that the underlying mechanism for PXR mediated 
repression is gene or promoter specific.  One important step to further confirm 
SUMOylation’s role is to identify SUMOylation site(s) in PXR and generate SUMOylation 
deficient PXR mutants.  However, current research in our laboratory using site-directed 
mutagenesis indicates that SUMOylation can occur on multiple lysine sites within PXR and it 
is highly possible that when the major SUMOylation sites are mutated, SUMOylation can 
migrate to other lysine sites.  Another interesting aspect is to see whether SUMOylated PXR 
shares the same mechanism with LXR, LRH1 and PPARγ to interfere with the removal of 
corepressor complexes from the promoters of inflammatory response genes.  Since the 
activity of PXR is affected by multiple signaling pathways, further studies are required to see 
how different signaling pathways affect PXR SUMOylation and the ability of PXR to repress 
inflammatory response; whether post-translational modifications of PXR-interacting proteins 
contribute to PXR mediated repression on inflammation; and also, whether disease states alter 
the ability of PXR to repress inflammation.  
PXR has evolved to protect the body from toxic xenobiotic insults.  Its function is 
evolutionarily conserved, but there are some species differences.  For instance, PCN is a 
strong rodent PXR agonist, but it has little effect on human PXR.  Moreover, activation of 
the cyclic AMP-dependent protein kinase signaling pathway increases PXR-mediated gene 
activation in mouse hepatocytes, whereas the same signaling pathway represses 
PXR-mediated gene activation in rat and human hepatocytes (42).  Thus, it is important to 
look at PXR activity in different species.  In this chapter, we mainly focused on mouse PXR.  
However, SUMOylation of PXR is conserved between mouse and human PXRs, so are the 
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potential SUMOylation sites.  Our previous work showed that hPXR repressed inflammatory 
responses in human immortalized cell lines (26).  In rat, treatment with PXR ligands has also 
been shown to ameliorate intestinal inflammation, indicating the anti-inflammatory function 
of PXR is evolutionally conserved through different species (43, 44).   
The data presented here indicate that PXR activation has both an early negative 
regulatory role in LPS-inducible expression of key inflammatory mediators like IL-1β and 
IL-6, as well as a likely positive role in regulating ligand-inducible expression of the secreted 
form of IL-1Ra protein at later time points.  The working model for the feedback inhibition 
and resolution of the inflammatory response in hepatocytes through time is depicted in Figure 
4-9.  Based on the observations discussed above, we propose that following injury or 
infection, low stoichiometric amounts of SUMO-modified PXR transcriptionally suppresses 
pro-inflammatory mediators like IL-1β and IL-6, while the remainder of PXR protein is likely 
ubiquitinated and subsequently degraded by the 26S proteasome in a signal dependent manner.  
Consistent with the hypothesis, significant lower levels of PXR protein are detected in 
endotoxin-treated mice (45).  As the inflammation ensues through time, newly synthesized 
PXR protein becomes available for up-regulating ligand-dependent expression of novel or 
alternative PXR-target genes including IL-1Ra, possibly through cryptic or low-affinity 
PXR-response elements.  Moreover, peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α), a strong PXR co-activator, is known to control the expression 
of IL-1Ra in the liver (46).  In this way, PXR activation gains anti-inflammatory function 
and plays an active role in the resolution of inflammatory response. 
Understanding the underlying mechanism of how PXR converts from a positive regulator 
of xenobiotics clearance to a repressor of inflammatory response will lead to the development 
of new treatments to control inflammation.  Further understanding of PXR together with 
other NRs will definitely lead to improvements on current drug therapies and also the 
development of novel drugs. 
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Figure 4-9. Model of the Mechanism of PXR-mediated Interaction with the 
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Chapter 5: Future Directions 
5.1 Identification of Post-Translational Modifications Sites within the PXR Protein. 
The identification of PXR modification sites provides information for crosstalk between 
different post-translational modifications and is an important step towards understanding the 
biological roles of different modifications.  The identification of PXR modification sites has 
always been a research interest in our laboratory.  While the mutation of acceptor lysine to 
arginine supposes to inhibit modifications like ubiquitination and SUMOylation, our data 
indicate that neither SUMOylation nor ubiquitination can be totally knocked out by single 
lysine mutation.  The data indicate that there are multiple modification sites.  Or the 
modification can be migratory.  In other words, when the major modification site(s) is 
unavailable, the modification can occur at sites that are not modified under normal conditions.  
Beside biochemical methods such as site-directed mutagenesis, another commonly used 
approach to identify modification sites is mass spectrometry.  In vitro SUMOylation and in 
vitro ubiquitination assays are wildly used for this purpose (1, 2).  Because the stoichiometry 
of PXR SUMOylation is extremely low, several improvements were employed to increase 
PXR SUMOylation in in vitro assays, including escalating protein amounts, incorporating 
identified SUMO E3 ligase and increasing the reaction time.  After the improvements, 
SUMOylated PXR bands can be visualized in Coomassie Blue stained gels (As shown in 
Fig.5-1).  All these efforts laid the foundation for mass spectrometry-based identification.  
Here we only used SUMOylation as an example.  Similar approach can be applied to other 





Figure 5-1.  In Vitro SUMOylation Assay for GST-hPXR-LBD.  20 μl reactions 
containing 8μl of purified GST-hPXR-LBD, 2 μl of E1 enzyme (Enzo Life Sciences), 2 μl of 
E2 enzyme (Enzo Life Sciences), with or without 2 μl of PIASy together with 1μl purified 
SUMO3 Q87R were incubated at 37 °C in the presence or absence of Mg
2+
-ATP for 3 hours.  
After the addition of 20μl of 2 × SDS-PAGE gel loading buffer, 5μl sample was subjected to 
western blot analysis with antibodies that recognize PXR (sc-48340, Santa Cruz) and the rest 




of the biological functions and physiological roles of different modifications. 
5.2 The Development of Research Models for PXR 
The species difference of PXR is well-recognized, which hinders the translation of data 
generated from animal models to clinical outcomes.  Currently, for PXR studies, the most 
relevant model is primary human hepatocytes.  However, the limited source of human liver 
remains to be an issue, and regardless hepatocyte cultures cannot fully represent the in vivo 
situation.  Using murine hepatocytes, Zellmer et al. showed that after isolation, hepatocyte 
cultures showed major alterations in gene expression compared to the in vivo situation (3).  
The mRNA levels of various CYP450 enzymes are differentially expressed over time in 
hepatocyte cultures.  For the first 1–2 days, time-dependent decreases in the mRNA levels 
are observed for all major CYP450 genes.  Then the expression levels of some enzymes like 
CYP3A4 and CYP2D6 can recover to a certain degree, while others including CYP1A2 and 
CYP2E1 do not recover (4).  To overcome the differences between primary cultures of 
hepatocytes and the in vivo situation, increasing modifications have been made to the culture 
system, like the collagen sandwich cultures, which can preserve the polarized hepatocytes 
morphology and facilitate long-term culture.  Many commercially available novel 
hepatocyte culture models are developed.  For example, the hepatocytes are cultured 
together with non-parenchymal cells.  Using the Transwell approach and the hanging drop 
strategy, 3D structure is allowed to develop in the culture system (5).  
As developments have been made to in vitro cell culture systems, the progress in mice 
model development is also remarkable.  Transgenic mice expressing human PXR are 
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generated (6, 7).  The PXR of a transgenic mouse can be selectively activated by human 
PXR ligand rifampicin, suggesting the model overcomes some aspect of species specificity.  
The generation of double transgenic mice expressing both human PXR and human CYP3A4 
provides another way to overcome the limitations of transgenic mouse models (8).  The 
development of transgenic mouse models allows us to study the function of PXR in a whole 
animal system to reveal the physiologic functions of PXR.  Even though both in vitro and in 
vivo models have improved significantly, they still need to be interpreted with caution when 
experimental data are extrapolated to humans.   
5.3 Regulation of PXR in Patho- and Physiological Conditions 
As discussed previously, PXR plays regulatory roles in many patho- and physiological 
conditions.  Activation of PXR is suggested to be beneficial in the treatment of diverse 
diseases, like cholestasis and inflammatory bowel diseases (9, 10).  Many widly used 
medications later turned out to be PXR ligands and their efficacy is at least partially through 
the activation of PXR, as in the case of rifaxinmin (11).  Previously, activation of PXR has 
mainly been suggested to treat various metabolic diseases.  However, recent studies indicate 
that the therapeutic value of PXR is wider than formerly thought.  One example is in the 
treatment of Alzheimer’s disease (AD).  P-glycoprotein (Pgp), also known as multidrug 
resistance protein 1 (MDR1), is a well-characterized target gene of PXR.  Pgp is expressed 
in many tissues including intestinal epithelium, hepatocytes, and in the capillary 
endothelial cells comprising the blood–brain barrier.  Amyloid β-peptide (Aβ) accumulation 
and inflammation among many other factors are the central components of AD 
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pathophysiology.  Pgp regulates the clearance of Aβ from the brain into the blood (12).  
Using transgenic human APP (amyloid precursor protein)-over-expressing mice, Hartz et al. 
showed that activation of PXR by PCN restored Pgp expression and transport activity 
in brain capillaries and significantly reduced brain Aβ levels (13).  Moreover, the 
anti-inflammation property of PXR also contributes to the management of AD.  Since PXR 
activators manifest favorable effects on AD management, PXR is implicated as an emerging 
therapeutic target for AD.  While the primary function ascribed to PXR is the homeostatic 
control of steroids, bile acids, and xenobiotics, the wide distribution of PXR indicates that it 
might be involved in many other pathways.  The identification of novel roles of PXR in 
different patho- and physiological conditions, novel ligands and novel target genes is an 
important aspect of PXR research.  The broadening of our understanding of PXR may lead 
to novel therapeutic strategies, just like the case in AD treatment.   
On the other hand, activation of PXR is not without risks.  In the transgenic mice where 
PXR is constitutively activated, growth retardation, hepatomegaly and histological liver 
toxicity are observed, suggesting that sustained activation of PXR can be harmful (7).  
Furthermore, it is obvious that activation of PXR is involved in adverse drug-drug 
interactions, especially in patients who take multiple medications.  If one drug is a PXR 
ligand, the activation of PXR can lead to accelerated metabolism and clearance of other 
co-administered medications.  For medications with narrow therapeutic indices, like digoxin 
and warfarin, alterations in metabolism and clearance can often lead to life-threatening 
consequences.  Studies of PXR have deepened our understanding of adverse drug-drug 
interactions and allowed us to predict the potential of drug-drug interactions in the early stage 
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of drug development.  Nowadays, drug candidates are routinely tested for their ability to 
activate PXR in pharmaceutical companies.  The compounds that activate PXR will be 
withdrawn or modified to minimize their PXR activating property, which can prevent 
late-stage clinical failures and minimize the costs.  In addition to adverse drug-drug 
interactions, PXR activation may also correspond to the underlying mechanism for some 
drug-induced pathological conditions, like impaired immune responses and hepatic steatosis.  
Recent studies indicate that post-translational modifications also regulate the activities of 
PXR, representing new modes of PXR-mediated gene regulation.  Data generated in our 
laboratory indicate that the presence of corepressor proteins like SMRT and NCoR can 
increase the SUMOylation level of PXR (As shown in Fig. 5-2).  Whether other PXR 
interacting proteins also regulate post-translational modifications of PXR, and ascertaining if 
these regulations occur in response to metabolic, pathogenic, and xenobiotic stress remain 
interesting issues to be explored.  Furthermore, the identification of molecules that directly 
modulate PXR post-translational modification status without activating PXR is another 
important aspect of PXR research.  Similar research has been done with PPARγ.  It has 
been shown that blocking CDK5-mediated PPARγ phosphorylation by non-agonistic binding 
produces anti-diabetic effects without some of the side effects of thiazolidinediones (14).  
Targeting the post-translational modifications, instead of direct PXR agonism, may be a better 
way to get therapeutic effects and avoid potential side effects like adverse drug-drug 
interactions.  





Figure 5-2.  Corepressor Proteins Increase PXR SUMOylation.  Expression vectors 
encoding PXR, His-tagged SUMO3, Ubc9, PIASy, SMRT and NCoR were transfected into 
HeLa cells as indicated in the figure.  48 hours post-transfection, cells were harvested in 
denaturing buffer and SUMOylated proteins were purified with nickel-linked agarose beads.  
Captured proteins were subjected to SDS–PAGE and subsequent western blot analysis using 




drug-drug interactions, but also to prevent drug resistance and tumor growth in cancer 
patients.  Furthermore, the inhibition of PXR may represent a novel management for 
steatosis treatment.  However, compared to the numerous PXR agonists that have been 
detected, the discovery for PXR antagonists has just begun.  Selective and non-toxic PXR 
antagonists are of great therapeutic potential. 
Over one-and-a-half decades after its discovery, our knowledge on PXR has expanded 
from an orphan receptor to a well-characterized xeno- and endobiotic sensor with great 
therapeutic potentials.  Besides its role in maintaining cellular homeostasis, PXR also serves 
as an attractive target for the development of pharmacologic modulators for managing many 
metabolic and non-metabolic diseases.  The continued study of PXR will aid the 
development of novel, safe and effective therapeutic strategies, and help prevent drug-drug 
and disease-drug interactions in patients. 
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Appendix 1: The Generation and Characterization of 
PXR-SUMO/PXR-Ub Fusion Proteins 
It is reported that linear SUMO/Ub-fusion proteins behave similarly to SUMO and Ub 
conjugates and can be a useful tool to study SUMOylation and ubquitination (1-3).  While 
SUMO and ubiquitin modifications are highly dynamic and reversible, the generation of 
fusion protein can provide a form of protein that is constitutively attached to SUMO or 
ubiquitin.  To study the effects of SUMOylation and ubiquitination on PXR, PXR SUMO 
fusion proteins were generated by incorporating the SUMO at both the N terminus and C 
terminus of PXR in different PXR expressing vectors.  PXR ubiquitin fusion proteins were 
generated by incorporating the ubiquitin at the N terminus of PXR (Illustrated in Fig. S1-1A).  
The expression of the linear fusion proteins were confirmed using both PXR and SUMO/Ub 
antibodies, as shown in Fig. S1-1B-D.  After confirmation of the expression of fusion 
proteins, the transactivation ability of these novel constructs were examined.  Analysis of the 
XREM-Luc reporter gene assays showed that the fusion proteins could still be activated by 
the prototypical PXR ligand- rifampicin.  However, the fusion of SUMO or ubiquitin 
significantly reduced the transcriptional activity of PXR (As shown in Fig.S1-2).  
To test the hypothesis that SUMOylated PXR represses the inflammatory response, the 
SUMO fusion PXR construct was used in the NF-κB-Luc reporter assays.  As shown in 
Fig.S1-3, in the reporter alone group, treatment of cultured HeLa cells with hTNFα produced 
an approximate 12-fold increase in NF-κB reporter gene activity.  While the expression of 
hPXR effectively repressed TNFα-mediated NF-κB reporter gene activity, the SUMO fusion 
PXR had no further repression effect compared to the wild type PXR.  Since the NF-κB-Luc 
reporter used in the experiment only contains NF-κB-response elements, which is a highly 
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simplified model to study inflammatory response, it is possible that the repression of PXR on 
inflammatory response requires other transcription factors and their response elements.  The 
data presented in Chapter 4 also suggest that the ability of PXR to repress inflammatory 
response genes is gene- or promoter- specific.  Future experiments introducing both wild 
type and PXR SUMO fusion proteins into PXR-KO hepatocytes and testing the expression of 











































Figure S1-1.  The Expression of SUMO/Ub PXR Fusion Proteins.  (A)  Schematic 
representation of PXR SUMO and ubiquitin fusions.  For N-terminus fusions, SUMOs and 
ubiquitin, which lack one of the two glycines at the C terminus and the stop codon, were 
fused in-frame to full-length PXR.  For C-terminus fusions, the stop codon of full length 
PXR was removed before its fusion to SUMOs, which lack one of the two glycines at the C 
terminus of mature SUMOs.  The removal of one of the two glycines at the C terminus of 
mature SUMOs and ubiquitin prevents the fusion proteins from being processed by 
SUMO/De-SUMO and ubiquitination enzymes.  (B) Expression of N-terminus SUMO 
fusion proteins.  Hepa1-6 cells were transfected with plasmids encoding PXR or 
SUMO3-PXR fusion proteins as indicated in the figure.  Whole cell lysates were resolved by 
using 10% SDS-PAGE.  The blots were probed for both PXR (Santa Cruz) and SUMO3 
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(Cell Signaling) immunoreactivity. (C) Expression of C-terminus PXR-SUMO fusion proteins.  
Hepa1-6 cells were transfected with plasmids encoding PXR or PXR-SUMO fusion proteins 
as indicated in the figure.  Whole cell lysates were resolved by using 10% SDS-PAGE.  
The blots were probed for both PXR (Santa Cruz) and SUMO1/3 (Cell Signaling) 
immunoreactivity.  (D) Expression of N-terminus Ub-PXR fusion proteins.  Hepa1-6 cells 
were transfected with plasmids encoding PXR or Ub-PXR fusion proteins as indicated in the 
figure.  Whole cell lysates were resolved by using 10% SDS-PAGE.  The blots were probed 
































.  Figure S1-2.  Linear SUMO/Ub Fusion Decreases Transactivation of PXR in 
XREM-Luc Reporter Assay.  (A) CV-1 cells were transfected with the XREM-luciferase 
reporter gene together with plasmids encoding PXR or PXR SUMO fusion proteins as 
indicated in the figure.  24 hours after transfection, cells were treated with vehicle (0.1% 
DMSO) or 10 μM rifampicin for another 24 hours.  Luciferase activity was determined by 
using standard luciferase assay system (Promega).  The results are reported as fold-induction 
± S.E.M. and are normalized to β-galactosidase activity (**=p<0.001).  (B) CV-1 cells were 
transfected with the XREM-luciferase reporter gene together with plasmids encoding PXR or 
Ubiquitin PXR fusion proteins as indicated in the figure.  24 hours after transfection, cells 
were treated with vehicle (0.1% DMSO) or 10 μM rifampicin for another 24 hours.  
Luciferase activity was determined by using standard luciferase assay system (Promega).  
The results are reported as fold-induction ± S.E.M. and are normalized to β-galactosidase 







Figure S1-3.  PXR SUMO Fusion Protein Has No Further Effect on the 
Transrepression of PXR in NF-κB-Luc Reporter Assay.  HeLa cells were transfected with 
the NF-κB-luciferase reporter gene together with plasmids encoding PXR or SUMO3-PXR 
fusion protein as indicated in the figure.  After transfection, cells were pre-treated with 10 
μM rifampicin for 24 hours and then co-treated with hTNFα (10 ng/ml) for another 6 hours 
before luciferase activity was determined by using standard luciferase assay system 
(Promega). The results are reported as fold-induction ± S.E.M. and are normalized to 
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Appendix 2: The Effects of PXR Activation on MAPK Activities 
The mitogen-activated protein kinases (MAPKs) are a family of signal transduction 
proteins that can convert extracellular signals, such as the presence of mitogens, inflammatory 
cytokines, and growth factors, to the intracellular pathways through a series of 
phosphoryltaion events.  Three subfamilies of MAPKs are well-characterized: ERKs 
(extracellular signal-regulated protein kinases), JNKs (c-jun N-terminal kinases) and the p38 
(1).  Activation of PXR has been shown to elicit p38 phosphorylation and lead to cell 
migration.  The induction is mediated by GADD45β.  GADD45β is known to activate p38 
signaling pathway through direct interaction with MTK1 (also known as MEKK4) (2, 3).  
PXR can directly activate GADD45β gene expression by binding to GADD45β promoter and 
then activate the p38 signaling pathway (4).  The notion that PXR activation might affect 
MAPK activities prompted us to further the study using wild type mouse hepatocytes. 
After isolation, primary cultures of mouse hepatocytes were allowed to attach overnight.  
Firstly, time-dependent analysis was conducted.  Several well-known activators of MAPKs, 
including LPS, TNFα, IL-6, and HGF (hepatocyte growth factor), were used in the 
experiment.  Wild type mouse hepatocytes were treated for different time points (10 min, 
30min, and 60 min) before whole cell lysates were harvested and subjected to Western Blot 
analysis.  As shown in Fig. S2-1, for all the treatments, phosphorylation of MAPKs showed 
robust induction at 30 min, and the phosphorylation levels decreased at 60 min.  The data 
indicate that phosphorylation of MAPKs is a quick and transient process.  Since in our 
experimental settings, phosphorylation levels of MAPKs showed great induction at 30 min, 
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for the following experiments, 30 min was chosen for MAPKs stimuli treatment.  
Next we sought to determine how PXR activation alters the phosphorylation events of 
MAPKs.  Wild type mouse hepatocytes were pre-treated with vehicle or 10 μM PCN for 48 
hours.  Cell cultures were then divided into four experimental groups and were treated for an 
additional 30 min with either vehicle, PCN alone, MAPKs stimuli alone, or PCN and MAPKs 
stimuli together.  Then whole cell lysates were harvested and subjected to Western Blot 
analysis.  As shown in Fig.S2-2 (A), treatment of PCN alone had no significant effect on the 
phosphorylation of ERK and JNK.  However, activation of PXR led to increased 
phosphorylation of p38.  This is in accordance with the previous publication (4).  When 
compared the co-treatment groups to the stimuli alone treatment groups, the pre-activation of 




















Figure S2-1.  The Effects of Different Stimuli on the Phosphorylation Status of MAPKs.  
Cultures of primary mouse hepatocytes were isolated from wild type mice.  After overnight 
attachment, hepatocytes were treated with LPS (20 μg/ml), TNFα (20 ng/ml), IL-6 (40 ng/ml), 
and HGF (20 ng/ml) for indicated time points.  Whole cell lysates were harvested and 
subjected to SDS–PAGE and subsequent western blot analysis using (A) ERK/PO4-ERK, (B) 
JNK/PO4-JNK, and (C) p38/PO4-p38 antibodies (Cell Signaling).  β-actin was used as 



















Figure S2-2.  The Effects of PXR Activation on the Phosphorylation Status of MAPKs.  
Cultures of primary mouse hepatocytes were isolated from wild type mice.  (A) Hepatocytes 
were treated with vehicle (0.1% DMSO) or 10 μM PCN for 48 hours before whole cell lysates 
were harvested and subjected to SDS–PAGE and subsequent western blot analysis using 
ERK/PO4-ERK, JNK/PO4-JNK, and p38/PO4-p38 antibodies (Cell Signaling).  β-actin was used 
as loading control.  (B-D) Wild type hepatocytes were treated with vehicle (0.1% DMSO) or 10 
μM PCN for 48 hours before the treatment with LPS (20 μg/ml), TNFα (20 ng/ml), IL-6 (40 
ng/ml), and HGF (20 ng/ml) for 30 min.  Whole cell lysates were harvested and subjected to 
SDS–PAGE and subsequent western blot analysis using (B) ERK/PO4-ERK, (C) JNK/PO4-JNK, 
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